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ABSTRACT  
  
 The enzyme monoamine oxidase (MAO) is linked to mental disorders such 
as depression and neurodegenerative diseases. Our laboratory has recently 
demonstrated that increases in calcium (Ca2+) can enhance MAO activity and that 
this might contribute to Alzheimer disease (AD). AD has been linked to gain-of-
function mutations in the presenilin-1 (PS-1) protein that not only promote the 
generation of the toxic amyloid-β peptide, but that also alter intracellular Ca2+ 
availability. 
 Radioenzymatic MAO assays were used to demonstrate that over-expression 
of different AD-related PS-1 mutant proteins, i.e. Y115H, ΔEx9 and M146V, in 
hippocampal-derived HT-22 cells alter either basal and/or Ca2+-sensitive MAO-A 
activity.  The effects of PS-1 mutant proteins on the availability of intracellular Ca2+ 
are not consistent suggesting that this may not be the primary means of regulating 
MAO activity. The sensitivity of MAO to Ca2+ was also demonstrated in cortical 
(both MAO-A and MAO-B responded to Ca2+) and cerebellar (only MAO-A 
responded to Ca2+) samples from transgenic mice overexpressing the PS-1 (M146V) 
mutation. These changes in MAO coincided with changes in the availability of the 
neurotransmitters dopamine, noradrenaline and serotonin in the cerebellum, but not 
in the cortex, and reflect the known regional differences in neurotransmitter 
regulation. Immunoprecipitation studies and the observed increase in MAO-A 
activity following in vitro chemical inhibition of the γ-secretase complex 
(comprising several proteins including PS-1) support the notion that PS-1 
constitutively associates with MAO-A. These effects on Ca2+-sensitive MAO 
function could contribute to AD-related pathology and could also contribute to the 
depression often associated with AD. 
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1 INTRODUCTION 
 
 
1.1 Alzheimer disease  
  
 Alzheimer disease (AD) is the most prevalent neurodegenerative disease 
today and the third most common affliction, apart from cancer and cardiovascular 
disease, in the elderly (1, 2).  Two pathological hallmarks of AD are neurofibrillary 
tangles and amyloid plaques (3).  Neurofibrillary tangles are comprised of tau 
protein.  Tau is a microtubule associated protein that when phosphorylated 
dissociates from the microtubles forming insoluble paired helical filaments (PHF), 
which then combine to form intracellular neurofibrillary tangles.  Amyloid plaques 
are extracellular and are comprised mostly of the protein amyloid beta (Aβ).  Aβ, 
which can exist as a 40-mer or a 42-mer cleavage product derived from a precursor 
protein, is generally believed to be the main initiator of AD and promotes the 
amyloid cascade, which stimulates numerous cell pathways, including 
neurofibrillary tangle formation, to bring about neurodegeneration.  AD can occur 
early in life (familial AD) or later on (sporadic AD).  The direct cause of sporadic 
AD is still undetermined but is believed to arise from many factors including diet, 
age and stress.  Familial AD is associated with three genes, e.g. APP, PS-1, PS-2.  
Mutations in the amyloid precursor protein (APP) can increase total Aβ or promote 
the longer (42-mer) plaque-associated Aβ over its shorter (40-mer) form but only 
few familial AD cases are because of APP mutations.  The majority of the familial 
AD cases are due to mutations in either of two presenilin (PS) protein.  The PS 
proteins, PS-1 or PS-2, provide the functional core of the gamma (γ)-secretase 
complex, which cleaves Aβ from APP (3).  These two proteins are derived from two 
separate genes and share 60% sequence homology (4). Over 160 pathogenic PS-1 
1 
gene mutations have been found in people affected with familial AD, compared to 
PS-2 which has 10 associated familial AD mutations (3).  Because of this and other 
reasons, which will be elaborated on in the subsequent sections, the current thesis 
focused on the PS-1 protein.  
 There are relatively few treatments available for AD, most of which involve 
slowing down the degradation of the neurotransmitter, acetylcholine. However, the 
effects of these drugs offer only modest symptomatic relief, so better treatments are 
needed.  Some treatments currently in clinical trials include passive immunization of 
Aβ, Aβ aggregation inhibitors, γ-secretase inhibitors, nerve growth factor (NGF) 
therapy, antioxidants and calcium (Ca2+) channel antagonists (5).  Moreover because 
the onset of this disease is slow and insidious, and it is believed that Aβ plaques are 
only an end-point in the progression of the disease, earlier preventative measures are 
likely to be more beneficial.  In order to develop these prophylactic treatments, it is 
critical to elucidate the mechanisms leading to Aβ plaque formation and 
neurodegeneration, through cellular and animal models. Familial AD models, which 
are more aggressive than sporadic AD but have the same disease progression, often 
offer great insight into AD pathology and etiology.  As already mentioned, the most 
mutated gene in familial AD is PS-1, so examination of the role(s) of the PS-1 
protein, beyond simply contributing to Aβ formation, is necessary for understanding 
the disease process and defining better preventative and chronic treatments.  
 
 
1.2 Presenilin-1  
 
1.2.1 Gene and protein structure of presenilin-1 
 In 1995, a gene, S182, on chromosome 14q24.3 was found to be associated 
with early-onset familial Alzheimer’s disease (EOFAD), when mutated.  This gene 
and the subsequent protein was later named presenilin-1 (PS-1) (6).  The PS-1 gene 
is approximately 60 kilo-base pairs long and has a total of 12 exons with only 10 of 
those being coding exons (exons 3-12).  These coding exons transcribe a 1403 base 
2 
pair (bp) PS-1 protein (7). Initial hydropathy plots revealed that PS-1 has at 
minimum seven hydrophobic transmembrane helical domains connected by 
hydrophilic domains which include one large hydrophilic loop between 
transmembrane domains six and seven (6) (Figure 1.1). Aside from all of the above 
findings, there is nothing else known about the 3-D structure of PS-1, because it is a 
relatively new protein and no one has been able to crystallize it yet. 
 
1.2.2 Location of presenilin-1 
 Northern blot analysis has revealed that PS-1 mRNA is found in equal 
amounts in many brain regions (6).  In peripheral tissues such as the kidney, heart 
and skeletal muscle, PS-1 mRNA is expressed at the same level as in the brain 
except in the liver where there is very low expression (6). Presenilin-2 (PS-2) 
mRNA, on the other hand, is expressed at a much lower level throughout the brain 
and is found at much higher levels in peripheral tissues (heart, skeletal muscle and 
pancreas) (8)    
At the level of neurons, PS-1 is found mainly in neuronal dendrites and cell 
bodies and only somewhat in axons (9).  In the cells (neuronal and non-neuronal) of 
the brain, immunofluorescence has revealed that PS-1 is found mainly in 
intracellular membrane systems such as the endoplasmic reticulum (ER) and golgi 
apparatus (10), but reports do confirm its existence in other cellular areas such as the 
cell (11), nuclear (12) and mitochondrial membranes (13).  The entire γ-secretase 
complex, including the proteins APH-1, PEN-2 and nicastrin, is located at the 
mitochondria (14).  Furthermore this complex was found to be functionally active as 
well (14). This is extremely relevant to the current thesis work. 
 
1.2.3 Physiological functions of presenilin-1 
1.2.3.1 Catalytic core of the γ-secretase complex 
 The most well-known function of PS-1 is its role as part of the γ-secretase 
complex; this complex includes the proteins PS-1, APH-1, PEN-2 and nicastrin (15).  
The combination of these proteins at the plasma membrane, in their mature and 
active form, allow cleavage of specific Type 1 single transmembrane proteins such  
3 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1:  Protein structure of presenilin-1.  Commonly mutated amino acids 
are in red, two catalytic aspartate residues are in yellow and the exon junctions are 
noted too (modified image is from Hardy J and Selkoe DJ (16); reprinted with 
permission from AAAS). 
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as APP, notch and cadherins (17, 18).  For example, the first step in the formation of 
the Aβ peptide is the removal of APP’s large extracellular N-terminal  domain by β- 
secretase to form the transmembrane peptide fragment, C99 (Figure 1.2) (17).  Once 
the large ectodomain is removed, γ-secretase is able to carry out intramembrane 
proteolysis of the C99 peptide and form amyloid-beta peptides ranging from 38-43 
amino acids long (19).  In low amounts and in the form Aβ40 (i.e. the 40-mer) Aβ is 
believed to be involved in regulating ion channels and synaptic transmission (20) but, 
in AD γ-secretase is believed to decrease Aβ40 production so that Aβ42 (i.e. the 42-
mer) is the predominant peptide (19).  Once excreted from the cell, this form tends 
to be more fibrillogenic (21). PS-1, at the core of γ-secretase, accounts for 
approximately 80% of all Aβ produced in the brain and PS-2 accounts for the other 
20% (22).  Another important γ-secretase substrate is notch.  Notch is a protein that 
is important in cell fate during development and similar to APP, the large 
ectodomain of Notch is removed by a metalloproteases such as KUZ or TACE (23, 
24).  Then the resulting transmembrane protein is cleaved by γ-secretase, and a 
protein called NICD (notch intracellular domain) is released and translocates to the 
nucleus to up-regulate specific genes (25). 
 In order for the γ-secretase complex to carry out proteolysis, it was originally 
believed that PS-1 first undergoes endoproteolysis and becomes a functionally active 
N- and C-terminal heterodimer that forms a catalytic core to bind γ-secretase 
substrates (26).  A year later, it was discovered that PS-1 endoproteolysis occurs 
between threonine 291 and alanine 299 with the majority of cut sites at or around 
methionine 298 (27).  Furthermore, this group quantified the number and size of 
peptide fragments from a PS-1 familial AD mutant, Cys410Tyr (meaning that 
Cysteine410 was substituted with a Tyrosine in the PS-1 protein), and they 
discovered that this mutant was similar to PS-1 WT concerning its endoproteolysis 
(27), but was unable to process Notch (28). This illustrates that not all familial AD 
mutants alter PS-1 endoproteolysis and that PS-1 endoproteolysis may not guarantee 
an active γ-secretase.  Concerning PS-1’s catalytic core, it is a GxGD-type aspartyl 
protease that has two aspartic acid (Asp) residues, Asp257 and Asp385, found on 
PS-1’s transmembrane 6 and 7 domains, respectively (29, 30).  These residues are  
5 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2:  APP proteolysis by different secretases.  The Aβ peptide is produced 
first by removal of the APP N-terminal domain by β-secretase, then by 
intramembrane proteolysis via γ-secretase (modified image is from Brunkan and 
Goate (17); reprinted with permission from Wiley-Blackwell Publishing Ltd). 
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required for γ-secretase activity and if they are mutated then γ-secretase-mediated 
proteolytic processing cannot occur (29).  
 For the other proteins in the γ-secretase complex, their characteristics and 
roles are not well-established yet.  What is known about these proteins is that 
nicastrin is a single transmembrane protein with a large extracellular domain, APH-1 
has seven transmembrane domains and PEN-2 has two transmembrane domains (19).  
Moreover, PEN-2 is believed to bind to PS-1’s N-terminal fragment and activate PS-
1 endoproteolysis, while APH-1 acts as a scaffold for the entire γ-secretase complex, 
first binding to nicastrin and then to PS-1 and PEN-2 (31).  Finally, nicastrin uses its 
large ectodomain to recognize γ-secretase substrates that are bound to PS-1 and then 
moved to PS-1’s catalytic area to be cleaved (19). 
                    
1.2.3.2 Regulator of Ca2+ homeostasis 
 Although most of PS-1’s roles are related to its proteolytic activity, some 
groups have shown that PS-1 has functions not related to γ-secretase.  For example, 
full-length WT (wildtype) PS-1 in mouse embryonic fibroblasts (MEFs) can form 
low conductance Ca2+ channels in the ER, which is an organelle that stores Ca2+ (32).  
Moreover, these channels are responsible for the majority of passive Ca2+ that is 
leaked out of the ER.  In addition these same authors demonstrated that the 
catalytically inactive PS-1 mutant D257A has the same level of cation conductance 
as PS-1 WT, while two FAD associated mutants M146V and Exon 9 deletion (ΔEx9) 
had a lower or higher level of cation conductance, respectively (32).  A second 
research group found that WT PS-1 is involved in regulating Capacitative Calcium 
Entry or CCE (33).  CCE is believed to involve Ca2+ conducting membrane channels, 
located at the plasma membrane, that are physically linked to the inositol 
triphosphate (IP3) receptors on the ER membrane.  This interaction allows 
extracellular Ca2+ to enter the ER lumen and fill its Ca2+ store whenever IP3 receptor 
agonists stimulate ER Ca2+ release.  Yoo and colleagues (2000) found that when PS-
1 was knocked out in PS-1 mice or when cells were expressing the inactive PS-1 
D257A protein, there was a drastic increase in CCE compared to that observed in 
WT PS-1 mice (33).  Even more surprisingly was the finding that a CCE inhibitor, 
7 
SKF96365, was able to dose-dependently increase Aβ42 levels and other Ca2+ influx 
inhibitors, nifedipine and ω-conotoxin GVIA did not affect Aβ42 levels.  In contrast, 
increasing Aβ42 levels did not affect CCE (33).  These results demonstrate that WT 
PS-1 has a normal physiological role in CCE regulation and mutated PS-1 in familial 
AD may alter CCE leading to increased Aβ42.  
 
1.2.3.3 Neuroprotection 
 A recent study has provided evidence that the presence of WT PS-1 in 
heterozygous familial AD animals helps to guard against senile plaque formation 
(34).  These authors noted that transgenic APP mice that were heterozygous for PS-1 
WT and M146V (APP/PS-1M146V/+) has 3-4 times less plaque deposits than 
transgenic APP/PS-1 heterozygous null mice (APP/PS-1M146V/-) at 3 and 12 months 
of age.  Additionally the APP/PS-1M146V/- had a lower γ-secretase activity resulting 
in less Aβ40 formation and no changes in Aβ42 formation (34).  These results support 
a neuroprotective role for WT PS-1. 
 
1.2.4 Mutations in the presenilin-1 gene and their effects 
 There has been over 160 pathogenic PS-1 gene mutations found to date in 
people affected with familial Alzheimer’s disease (FAD), compared to PS-2 which 
has 10 associated FAD mutations (4).  Although there have been findings of people 
with sporadic AD to have the PS-1 gene mutated, the cases are few (35).  Almost all 
of the PS-1 mutations are point mutations with the greater part being the missense 
type, meaning that one nucleotide is different from the normal PS-1 gene and this 
single change codes for a different amino acid.  Even with such a minute alternation 
there can be an immense effect seen at the cellular and organism level. 
 
1.2.4.1 Cellular effects in AD 
 The two hallmarks of AD are neurofibrillary tangles and amyloid plaques, 
both of which are found, to various extents, in individuals with PS-1 mutations.   
 For the most part, PS-1 missense mutations will increase the production of 
the more fibrillogenic Aβ42 (the formation of this peptide was discussed in section 
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1.2.3.1.) (36, 37) and this will lead to the formation of amyloid plaques. Aβ42 
peptides oligomerize extracellularly and aggregate with other factors to form 
amyloid plaques.  These plaques then activate astrocytes and microglia to cause 
neuron dysfunction and eventually neuron death (16).  PS-1 mutations are also 
associated with the other hallmark of AD pathology.  As previously discussed, 
neurofibrillary tangles (NFTs) are formed from hyperphosphorylation of tau protein, 
which is thought to occur through many paths, one of which is Aβ initiated (38).  
Thus, mutated PS-1 proteins can increase Aβ production which leads to stimulation 
of kinases that phosphorylate tau.  Moreover, the specific PS-1 mutants M139V, 
I143F, G209V, R269H and E280A are all shown to promote neurofibrillary tangles 
at a much higher rate than in sporadic AD (39). 
 Other less common neuropathological changes associated with PS-1 
mutations are amyloid angiopathy, Pick bodies and cortical Lewy bodies (40). 
 
1.2.4.2 Clinical phenotype effects in AD 
 There are a vast amount of clinical symptoms that present to different 
degrees in each patient with EOAD associated with PS-1 mutations.  These 
symptoms are mostly the same symptoms which are found in sporadic AD, although 
some PS-1 mutations have been found to be linked to one or two of these 
characteristics more prominently.  For example, there have been over 30 familial AD 
PS-1 mutations such as M139V, M146V, G209V, ΔEx9 and E280A each connected 
to prominent seizures, myoclonus, parkinsonism, extrapyramidal signs and spastic 
paraparesis, and over 20 other PS-1 familial AD mutations such as M146I, M146L, 
L250S, R269H and ΔEx9 that are related to obvious psychiatric symptoms 
(agitations, hallucinations, depression and delusions) and aphasia (40).  Other 
phenotypic effects such as cerebellar ataxia are not as prevalent, with only 10 or less 
PS-1 familial AD mutations showing a higher incidence of these signs (40). 
 Because of the abundant symptoms that EOAD patients have, one of the 
easiest ways to categorize familial AD mutations is by the age of onset of clinical 
features.  For example, some people with the more aggressive gene mutations such 
as M233L, M233V, L235P and Y256S are observed to have decreased cognition 
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before age 30, while others have an age of onset just before 60 years old (40).  
Surprisingly, even with the earlier age of onset these PS-1 mutation usually do not 
produce more Aβ42 than the other familial PS-1 mutations, as shown in many cell 
culture studies (36). 
 
1.2.5 Targeting PS-1 and/or γ-secretase for inhibition 
 There are several approaches one can take in targeting PS-1 because of the 
complex nature of this protein and the entire γ-secretase complex.  One could 
develop molecules that block the substrate binding site or catalytic site directly, or 
the molecule could bind to another area of PS-1 and allosterically modulate these 
sites.  Also one could try to promote PS-1 to cleave substrates more specifically 
increasing the Aβ40:Aβ42 ratio through alterations of PS-1 or any of the other γ-
secretase proteins.  
   
1.2.5.1 Inhibition of PS-1 and/or γ-secretase in research 
 For research purposes there have been several γ-secretase inhibitors used. 
However, these compounds are not used clinically since high concentrations are 
needed for any antagonistic effect and/or they are non-specific protease inhibitors 
that are fatal if used in any whole biological system (41).  In 2001, a class of small 
molecule inhibitors including one named DAPT was found.  These inhibitors can 
specifically target γ-secretase so that only Aβ levels are reduced.  As well, in vitro 
assays showed that DAPT was not toxic to the cell and in vivo there was a 
significant decreases in Aβ levels observed (41).  More recently, there was another 
finding pertinent to our research because two compounds were found to be more 
selective in their antagonistic properties.  Until now, all γ-secretase inhibitors 
including the small molecule inhibitors were not selective for PS-1 or PS-2 
containing γ-secretase, but Zhao et al (22) were able to determine that the 
sulfonamide compounds, BMS299897 and ELN318463, were more selective for 
inhibiting PS-1 and only at much higher concentrations did they inhibit PS-2. 
 
1.2.5.2 Inhibition of PS-1 and/or γ-secretase in AD 
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 As already mentioned, most of the clinical PS-1 mutations increase the 
longer or more fibrillogenic form of Aβ.  Due to this, initially pharmacological 
inhibition of γ-secretase was believed to be beneficial in AD. Yet it was found that 
since γ-secretase has other substrates critical for proper function and development 
such as Notch, its inhibition in animals caused many adverse effects.  In the APP 
transgenic mouse model for AD, the mice were given the γ-secretase inhibitor, LY-
411,575 (42).  At the doses required for any significant reduction of Aβ, there were 
also serious effects on the differentiation and maturation of lymphocytes and 
intestinal cells (42).  Therefore more selective and potent inhibitors of PS-1 and/or γ-
secretase are needed for use in AD patients.  These inhibitors would not only be 
more selective for APP processing, but would also reduce the more fibrillogenic 
Aβ42 and increase the other less toxic and more soluble short forms of Aβ.  Some 
problems which have been encountered so far in developing pharmacological PS-1 
inhibitors are that the PS-1 knock-out is embryonic lethal, probably due to the fact 
that Notch is not cleaved and proper development is impeded (43).  In addition, the 
γ-secretase complex has as yet to be crystallized so designing drugs based on its 
structure is not currently possible (43).  Even with all of these obstacles there have 
been some inhibitors discovered with lots of promise.  One example are the 
nonsteroidal anti-inflammatory drugs (NSAIDs).  These drugs were discovered to be 
specific allosteric modulators of PS-1 and have been shown to maintain total Aβ 
levels, but to increase the short form of Aβ and decrease the Aβ42 form 
independently of the NSAID’s ability to inhibit cyclooxygenase (COX) (44).  These 
inhibitors will likely help people with AD, but it is also important to remember that 
not all aspects of AD are related to the degree of Aβ plaque deposits, so looking at 
other roles for PS-1 and/or other proteins involved in AD are necessary for a 
complete treatment of the disease.  
 
 
1.3 Monoamine Oxidase  
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 Monoamine oxidase (MAO) was first discovered in 1928 by the graduate 
student Mary Hare, who observed that in liver extracts tyramine undergoes oxidation 
and deamination through an unknown enzyme, which she named tyramine oxidase 
(45).  A decade later two other enzymes, aliphatic amine oxidase and adrenaline 
oxidase, were discovered and Blaschko et al (46) noticed that these two enzymes 
and tyramine oxidase were similar in their chemical reaction, pharmacological 
inhibition, animal distribution and substrates, so he concluded that these were 
actually one enzyme, which he labeled amine oxidase. This amine oxidase was later 
called monoamine oxidase by E.A. Zeller (47) and it’s enzymatic substrates would 
subsequently include many other amines. 
   
1.3.1 Gene and protein structure of MAO-A and MAO-B 
 There are two forms of MAO: monoamine oxidase-A (MAO-A) and 
monoamine oxidase-B (MAO-B).  The first groups to determine the sequences of 
both of these enzymes were Bach et al (48) and Hsu et al (49).  They found that the 
human MAO-B gene is 2498 nucleotides long (of which the first 78 and last 858 
nucleotides are not translated) and the human MAO-A gene is 1937 nucleotides long 
(of which the first 73 and last 301 are not translated).  The human MAO-A protein is 
527 amino acids long with a molecular weight (MW) of 59.7 kDa, and the human 
MAO-B protein is 520 amino acids long with a MW of 58.8 kDa.  Moreover the two 
amino acid sequences were found to be 70% identical, yet even with this high 
homology MAO-A and -B were hypothesized not to be splice variants or products of 
different post-translational processing, but rather that they were derived from two 
separate genes (48, 49).  A year later, the bovine MAO-A protein sequence was 
elucidated and compared to the amino acid sequence of bovine MAO-B (50) and 
confirmed that both proteins derive from different genes. 
 Two research groups simultaneously found that the two genes of human 
MAO-A and MAO-B were linked to the X chromosome and their exact locations 
were neighboring each other on Xp11.23 (51, 52).  On this chromosome, both MAO 
isoforms have a total of 15 exons with exactly the same order of exons and introns 
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(53).  Also the highest conserved exon was exon 12, mostly likely because it codes 
for the protein area where MAO’s co-factor, FAD, binds (53).  
 Concerning their 3-dimensional (3-D) structure, both MAO isoforms have 
four specific domains: three are hydrophyllic domains comprised of the ADP 
binding domain, the cofactor FAD binding domain and a substrate binding domain, 
and the third is the hydrophobic C-terminal domain (Figure 1.3 and 1.4).  
Specifically for human MAO-A, the beginning N-terminal amino acid residues make 
up an ADP binding domain (48, 49) and the subsequent amino acids 13-88, 220-294 
and some C-terminal amino acids, 400-462, make up the FAD binding domain (the 
C-terminal amino acids Ser-Gly-Gly-Cys-Tyr are specific for covalent binding of 
FAD); the central residues of 89-219 and 295-399 make up the substrate binding 
domain; lastly, the end residues of 463-527 make up the transmembrane C-terminal 
domain (54).  Human MAO-B, depicted in Figure 1.4, has the same initial N-
terminal amino acids making an ADP binding domain (48, 49) and  the next amino 
acids 4–79, 211–285 and some C-terminal amino acids, 391–453, make up the FAD 
domain; the central residues of 80–210, 286–390 and 454–488 make up substrate 
binding domain; lastly, the end residues 489-520 make up the transmembrane C-
terminal domain (55).  In their active folded conformation these isoforms are almost 
exactly identical.  The only major difference in their 3-D shape is in their substrate 
cavities.  The two cavities are made up of 20 amino acids but seven of the amino 
acids are different (54).  These differences allow for MAO-B to have an extra cavity 
termed the entrance cavity.  For all MAO-B substrates, they first must enter a 
smaller entrance cavity, then move into a larger substrate cavity by a concerted 
movement of four amino acids, Phe168, Leu171, Ile199 and Tyr326, that allow 
substrates to pass through (56).  These two cavities may become a single cavity with 
specific substrates such as deprenyl (54, 55).  In addition, they both have a cavity 
loop (in MAO-A it is comprised of amino acids 210-216 and in MAO-B it is 
comprised of amino acids 201-206), but the conformation of the MAO-B loop is 
more condensed and folded due in part to the seven dissimilar amino acids (54).  
Taken together, these two variations make the MAO-B cavity longer and narrower  
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Figure 1.3:  3-Dimentional structure of human MAO-A.  The MAO-A protein is 
depicted using the “ribbon” format. The red color denotes the substrate binding 
domain, the blue denotes the FAD binding domain and the green denotes the C-
terminal domain (ADP binding domain is not shown) (image from De Colibus et al 
(54); copyright (2005) National Academy of Sciences, U.S.A). 
 
 
 
 
 
14 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4:  3-Dimentional structure of human MAO-B.  The MAO-B protein is 
depicted using the “ribbon” format.  The red color denotes the substrate binding 
domain, the blue denotes the FAD binding domain and the green denotes the C-
terminal domain (ADP binding domain is not shown) (image from Binda et al (55); 
copyright (2003) National Academy of Sciences, U.S.A). 
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than the MAO-A cavity, thereby accounting for differences in substrate type and 
affinity. 
 
1.3.2 Location of MAO-A and MAO-B 
 MAO has been found in mostly all eukaryotic organisms from parasitic 
worms to sea urchins to primates, and in vertebrates it is also found in all tissues 
(46), although some tissues such as the human placenta and skin fibroblasts express 
only MAO-A, and platelets and lymphocytes express only MAO-B (57).  In rat and 
non-human primate brains, immunohistochemical studies have found that MAO-B is 
mostly in astrocytes (and not oligodendrocytes), and in serotonergic neurons of the 
nucleus centralis superior and dorsal raphe nucleus, while MAO-A is mostly in 
catecholaminergic neurons in the locus coeruleus, substantia nigra and the 
periventricular region of the hypothalamus (58, 59).  Later studies on MAO-A and -
B in human brains confirmed these findings (60).  
 For MAO’s subcellular localization, it was generally believed, because of its 
specific enzymatic reaction, that MAO was located specifically at the mitochondria.  
This was first demonstrated by Cotzias and Dole (61), and then substantiated by 
several others, including Rodriguez De Lores Arnaiz and De Robertis (62), Oswald 
and Strittmatter (63), and Gorkin (64).  Whether or not MAO was located on the 
outer or inner mitochondrial membrane was harder to establish because of possible 
contamination when separating the mitochondrial membranes and mitochondrial 
compartments.  Even with these difficulties, MAO was ultimately shown to reside 
on the outer mitochondrial membrane (65, 66).  
 
1.3.3 Functions of MAO-A and MAO-B 
 MAO is an enzyme that catalyzes the oxidative de-amination of endogenous 
and exogenous primary, secondary and tertiary amines.  In order for this enzyme 
reaction to occur the cofactor, FAD, must be covalently bound to MAO.  Therefore 
MAO is classified as part of the flavoproteins.  The exact reaction, reviewed in 
Binda et al (56), begins with the MAO-FAD complex (FAD is in its oxidized form) 
binding and oxidizing its substrate (an amine), thereby reducing FAD.  The reduced 
16 
FAD then binds oxygen, allowing it to be re-oxidized and this leads to the 
production of hydrogen peroxide.  As a result of the FAD re-oxidization, the bound 
imine (the oxidized amine substrate) is released from the MAO-FAD complex and is 
spontaneously hydrolyzed (ie. without the use of an enzyme) to an aldehyde, 
releasing ammonia as a by-product (56).    
 The substrates for MAO-A and MAO-B are numerous and since these two 
enzymes have similar amino acid sequences, they also have equal affinities for 
substrates such as dopamine and adrenaline (67).  On the other hand, the slight 
differences in their respective sequences allow both isoforms to have different 
affinities for particular substrates too.  So far, it is known that MAO-A is more 
selective in its substrates than is MAO-B and only the neurotransmitter serotonin or 
5-hydroxytryptamine (5-HT) has a high affinity for MAO-A (68).  In contrast, the 
compounds phenylethylamine (PEA), benzylamine and 1-methyl-4-phenyl-1, 2, 3, 6-
tetrahydropyridine (MPTP) all have a high affinity for MAO-B (56).  
 In the peripheral nervous system, one major physiological role for both MAO 
isoforms is the oxidative deamination of tyramine from tyramine-rich foods such as 
cheese and beer (67).  When these foods or drinks are ingested then both enzymes in 
the intestine and liver break down tyramine, thereby blocking its uptake into the 
blood and its subsequent uptake into adrenergic neurons and stimulate noradrenaline 
release.  If enough noradrenaline is released, then a sympathetic response is initiated 
resulting in hypertension (67).  MAO is essential in the regulation of all 
sympathomimetic amines in food.       
 In the central nervous system, the metabolism of neurotransmitters such as 
dopamine, serotonin and noradrenaline by MAO is critical.  These neurotransmitters 
are routinely released, and in large amounts, into the synapse, so specific proteins 
such as MAO are involved in their degradation and clearance.  If not properly 
cleared, then chronic stimulation of the neurotransmitter’s post-synaptic receptor can 
occur, which can lead to receptor down-regulation.  In contrast, disease due to 
excessive MAO protein expression and/or activity usually is a consequence of 
receptor under stimulation. Many related therapies therefore target inhibition of 
MAO activity.  For example it is known that the release of the neurotransmitters 
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dopamine and noradrenaline are involved in generating the stress response.  As these 
neurotransmitters are MAO substrates it is not surprising that MAO-A (69) and 
MAO-B (70) knockout mice submitted to a forced swim test exhibit an increased 
stress response.  In keeping with this, some MAO inhibitors have been found to be 
beneficial in people with posttraumatic stress disorder, anxiety and panic disorders 
(71).   
 From a research perspective, MAO-B has an extremely important role when 
studying Parkinson’s disease. As mentioned above, MAO-B can metabolize the 
synthetic compound MPTP.  MPTP is a great research tool for scientists because 
MAO-B-mediated oxidative de-amination of MPTP leads to the neurotoxic 
metabolite 1-methyl-4-phenylpyridinium (MPP+) (72), which specifically targets the 
neuronal pathways associated with Parkinson’s disease. This was first demonstrated 
in rhesus monkeys whose brains were found to have a selective degeneration of 
neurons in the substantia nigra pars compacta (an area that is implicated in 
Parkinson’s disease) following administration of MPTP/MPP+ (73).   
 
1.3.4 MAO as a therapeutic target in disease 
 Prior to the 1950s, MAO was not implicated in any disease and much of the 
research still focused on its cellular characterization.  However, the use of a new 
drug, iproniazid, for the treatment of tuberculosis (TB), was not only effective in 
treating tuberculosis, but it also increased patient’s mood (47). As a result numerous 
investigations started for the use of iproniazid in depression, and this lead to the 
finding that iproniazid was actually an MAO inhibitor (47).  Very quickly thereafter, 
many MAO inhibitor drugs were produced and tested in patients with depression; 
however, scientists observed that the MAO inhibitors brought about serious 
hypertensive effects in patients (74).  This effect was speculated to be due to the 
previously described excessive dietary intake of tyramine-rich foods, such as cheese, 
and consequently became known as the ‘cheese effect’ (74).  Because of the side 
effects, MAO inhibitors were quickly pulled from the clinical trials until reversible 
and/or more selective inhibitors of MAO were found. 
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1.3.4.1 MAO-B as a target in disease 
 In 1965, a new irreversible MAO antagonist was developed called deprenyl 
or selegiline (75).  This compound was clearly more beneficial than the original 
MAO inhibitors in two ways; (i) it did not produce any cheese effect in patients 
because it inhibits catecholamine release in vascular smooth muscle and (ii) it 
specifically inhibits only the B isoform of MAO (75).  Additionally, it was noticed 
in a clinical study of 223 patients, that co-administration of deprenyl with an 
inhibitor of peripheral decarboxylase, benserazide, and levodopa improved the 
motor symptoms of the majority of Parkinson’s patients (76).  Subsequent work 
from this same group showed that deprenyl was also neuroprotective in that it 
delayed the degeneration of dopamine neurons in the striatum allowing people with 
Parkinson’s to live longer (77).  Recently a similar irreversible MAO-B antagonist 
called rasagiline, which does not have deprenyl’s amphetamine-like structure, was 
created and in vivo experiments have shown that it also increased dopamine levels in 
the striatum (78) and mediated neuroprotection in vitro (79).    
 MAO-B has been linked to the addiction seen in many cigarette smokers.  By 
using specific radiotracers and positron emission tomography (PET), the brains of 
smokers were found to have a reduced level of MAO-B, compared to non-smokers, 
in all brain regions including the frontal cortex, cerebellum, thalamus and basal 
ganglia (80).  This reduced MAO-B concentration was believed to happen through 
some chemical in cigarette smoke, but it has never been identified (80).  The 
decreased MAO-B is important because it allows for one of its substrates, dopamine, 
to avoid degradation and prolongs the dopamine reinforcing effects that are believed 
to contribute to the addictive behavior. 
 
1.3.4.2 MAO-A as a target in disease 
 J.P. Johnston (68) synthesized clorgyline or N-methyl-N-propargyl-3(2,4-
dichlorophenoxy) propylamine hydrochloride.  When characterizing this substance 
he found that there were actually two concentration-response curves that lead to his 
surmise that MAO was actually two enzymes, which he named MAO-A and MAO-
B, with different affinities for different substrates.  In this case, MAO-A was shown 
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to have an extremely higher affinity for clorgyline, making it the first recognized 
selective irreversible inhibitor of MAO-A (68).  Unfortunately because clorgyline is 
an irreversible MAO-A antagonist (MAO-A is the main culprit in producing the 
cheese effect) and in light of the successes with MAO-B antagonists, very little 
research focused on the therapeutic effects of inhibiting MAO-A.  Not until 
reversible MAO-A inhibitors such as moclobemide were discovered was its 
therapeutic potential revealed.  Moclobemide does not lead to the cheese effect and 
can increase the levels of neurotransmitters noradrenaline, serotonin and dopamine 
(81).  Its use as an anti-Parkinson drug is doubtful given the mild improvement in 
symptomatology (82), but its role as an anti-depressant has more potential because 
of its ability to increase the availability of serotonin, which has an important role in 
depression.  Bonnet et al (83) found that this drug was as effective as some tricyclic 
antidepressants and selective serotonin reuptake inhibitors, and there were no 
decreases in cognitive or psychomotor functions as with other antidepressants. As 
such, this MAO-A inhibitor may be useful in treating the elderly.  
 Concerning MAO-A’s interaction in cigarette smokers, it too was found to be 
decreased in all brain regions looked at in people who smoked compared to non-
smokers but the decrease was by only 28% (84) while MAO-B was decreased by 
40% (80).   
 
 
1.4 Presenilin-1 and monoamine oxidase in AD 
 
 Even though PS-1 and MAO have distinct physiological roles, there is 
evidence that both proteins may contribute to AD-related pathology and that a 
potential association between PS-1 and MAO is not an unreasonable hypothesis. 
 
1.4.1 Depression in AD 
 MAO is implicated in depression because the neurotransmitters which are 
altered in depression are substrates of MAO.  This is now corroborated by the 
observation that MAO inhibition has been effective in treating this disorder. 
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Depressive episodes or symptoms are also associated with AD in both the later 
stages (85) and, perhaps more importantly, the earlier preclinical stages of AD (86-
89).  Because the destructive cellular changes in AD occur many years before any 
clinical presentation of symptoms (90), it is quite possible that MAO-mediated 
effects contribute to the onset of AD symptoms.  In one study non-demented females 
in Mexico whose families had a history of familial AD were assessed for depressive 
symptoms (89).  Even though none of the women knew if they were carrying a PS-1 
gene mutation, the women who were carriers were found to be significantly more 
depressed than the comparable non-carriers (89).  Another study found that AD 
patients with the PS-1 E280A mutation (this mutation is associated with a broad 
range of onset for AD, i.e. between 36- 62 years) who developed the disease the 
earliest, i.e. before 46 years old, were four times more likely to have a history of 
depressive symptoms (91).  These studies implicate that MAO changes, manifested 
as depression, are part of the early neurochemical changes occurring in AD.    
 
1.4.2 Regional co-localization 
 It is well-known that post-mortem Alzheimer brains have significant cortical 
shrinkage and enlargement of ventricles including ventricles around the 
hippocampus.  Thus general brain atrophy is one of the final outcomes of AD but 
before this specific neuron systems degenerate including the cholinergic, 
noradrenergic and serotonergic systems (92).  These neuron systems all project 
extensively to the cortex and hippocampus, and the noradrenergic and serotonergic 
systems also project to the cerebellum (92).  Furthermore, it is of great importance to 
recall that noradrenergic and serotonergic systems are where MAO-A and MAO-B, 
respectively, exist abundantly in the brain (58, 59).  In addition, an examination of 
246 cortical brain samples showed that the frontal cortex from people with AD had a 
drastic increase in MAO mRNA compared to controls (93) and concerning this and 
other cortical regions, another group found that, in AD patients, there was an 
increase in MAO-A protein activity in the frontal cortex and MAO-B activity was 
increased in the temporal cortex (94).   
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 It has already been shown, for example by Smith et al (95) and Sayre et al 
(96), that part of the neuronal death seen in AD brains results from oxidative stress.  
The chief molecule associated with oxidative stress is the hydroxyl radical.  As 
already discussed above, MAO catalyzes the oxidative deamination of its substrate 
amines, generating hydrogen peroxide as a by-product of the reaction.  Through the 
Fenton reaction hydrogen peroxide can combine with the ferrous ion, Fe (II), 
producing the ferric ion, Fe (III), and the hydroxyl radical, which is toxic to DNA, 
lipids and proteins (20).  It is likely that this reaction contributes to AD 
neurodegeneration because Fe (II) and Fe (III) were found to specifically accumulate 
in the same areas as neurofibrillary tangles and amyloid plaques (97).  As well, a 
recent drug named M30 was developed which has the interesting characteristics of 
being both a selective brain MAO inhibitor and iron chelator (98).  Initial studies of 
this drug have already found its neuroprotective properties in in vitro models of cell 
death, although its effectiveness in treating AD is still being determined (98).  These 
combined data suggest that similarly to PS-1, MAO may play a role in the 
pathogenesis of AD, although this role for MAO is not necessarily independent of 
PS-1. 
 Subcellular localization studies have clearly demonstrated that MAO resides 
in the mitochondria, but it is only recently that PS-1 (but not PS-2) and all of the 
other γ-secretase-associated proteins have also been found in this same fraction (13, 
14).  The function of PS-1 and/or γ-secretase at the mitochondria is still unknown 
but what is clear is that these enzymes are not involved in processing APP to the 
toxic Aβ peptide, since in the mitochondria APP has a different orientation, than at 
the plasma membrane, i.e. its C-terminal is cytosolic and inaccessible for cleavage 
by γ-secretase (99).  Other areas where both PS-1 and MAO could interact include 
the ER and golgi apparatus because PS-1 is most abundantly expressed in these 
locations and MAO needs to pass through these membrane systems in order to get 
processed for targeting to the mitochondria.  Thus, the potential for these two 
proteins to interact is suggested first by their association with depression and second 
because of their neuronal and subcellular co-localization. 
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1.4.3 Ca2+ as the intermediate ion between PS-1 and MAO  
 The interaction between PS-1 and MAO may not be a direct one, but rather 
could rely on an intermediate molecule, the Ca2+ ion.  At normal concentrations, 
Ca2+ is needed for proper physiological functioning. However, in AD cytosolic Ca2+ 
levels are highly dysregulated, and PS-1 has been implicated in this dysregulation.  
Wild-type PS-1 and mutant PS-1 proteins are able to form passive Ca2+-leak 
channels in the ER membrane (the degree of effect of the mutant proteins is 
dependent on the mutation) (32).  In addition, cells expressing PS-1 mutant proteins 
(100-102) and PS-1 transgenic mice (standard and knock-in) (103-106) have an 
increased cytosolic Ca2+ level, compared to WT PS-1, that is believed to be mainly 
due to the alterations in the ER’s Ca2+ store and/or buffering ability.  For example, 
the ER Ca2+ release agonists carbachol and bradykinin and the ER Ca2+-ATPase 
inhibitor, thapsigargin, caused a significant increase in intracellular Ca2+ in PC12 
cells expressing a PS-1 mutant when compared to those expressing WT PS-1 (101).  
Moreover, mitochondria become less efficient in the production of ATP in the aging 
brain (107) and Aβ, cleaved via PS-1 mediated proteolysis of APP, can drastically 
reduce ATP levels in neurons and astrocytes (108).  This is important because in 
neurons, the mitochondria acts as stores for Ca2+ (taken up through its Ca2+ ATPase) 
when cells have an excessive amount of Ca2+, whereas in cortical astrocytes the 
mitochondria play a key role in storing Ca2+ at normal physiological levels (109). As 
such, a significant reduction in ATP levels would not only cause mitochondrial 
dysfunction, but it would also result in a significant increase in intracellular Ca2+. 
The ability of PS-1 to alter cytosolic Ca2+ levels is important because the level of 
MAO activity has been positively linked to Ca2+ concentrations.  Kosenko et al (110) 
and Cao et al (111) have demonstrated, in vitro, that the activity of mitochondrial 
MAO-A can be increased when Ca2+ availability increase.  Additionally, in the 
hippocampus, an area that is greatly affected in AD, there is an increase in basal free 
Ca2+ levels compared with other regions of the aging brain (112).  The mechanism 
behind this regionally-specific increase is not clear, but it might rely on the loss of 
expression of Ca2+ buffering proteins, such as calbindin (a cytosolic Ca2+-binding 
protein) and calreticulin (a Ca2+-binding protein in the ER lumen), as observed in the 
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hippocampus of 30 month-old rats (112).  These data could explain why the AD 
hippocampus is more susceptible to the PS-1- and MAO-generated hydroxyl radicals.   
 The dysregulation of cytosolic Ca2+ is a significant pathological mediator in 
AD as shown in patients taking Ca2+-related pharmacological interventions such as 
nimodipine and memantine.  Nimodipine, an L-type voltage-gated Ca2+ channel 
antagonist developed for high blood pressure, slowed the progression of AD in 227 
patients compared to those receiving the placebo (113).  Likewise, the NMDA (Ca2+ 
ion channel receptor) antagonist, memantine, has proven effect for moderate to 
severe AD cases (114). 
 
 
1.5 Research project 
 
 Research in the Cell Signalling Laboratory focuses on mechanisms of cell 
death in the CNS.  This thesis is aimed at examining the role of PS-1 in MAO-A 
function in models of Alzheimer disease. 
 
The specific hypothesis is that PS-1 regulates basal and Ca2+-sensitive 
MAO-A activities and that this contributes to the oxidative stress seen in AD. 
 
For this work three common FAD mutations, PS-1 Exon 9 deletion (ΔEx9), 
Y115H, and M146V were used and compared to PS-1 WT and the PS-1 D257A 
dominant negative mutant. 
 
1.5.1 Presenilin-1 constructs 
1.5.1.1 Exon 9 deletion 
 The PS-1 Exon 9 deletion (ΔEx9) genotype was first found in a British 
family with EOFAD (115).  Several other families with the ΔEx9 mutation were 
subsequently discovered and the mean age of onset was determined to be between 
45-55 (40).  Exon 9 comprises the amino acids (a.a.) 290-319 and these a.a. are 
deleted, in these families, by a missense mutation (a G to T nucleotide change) 
24 
occurring at the Intron and Exon 9 boundary that removes the splice recognition site.  
Moreover because this is an in-frame deletion, there is no change to the translated 
PS-1 protein except for a serine290cysteine substitution, which is at the junction of 
Exon 8 and 10 (115).  As discussed previously, it was found that PS-1 undergoes 
some post-translational processing, which includes endoproteolytic processing to an 
active heterodimer, and this processing is disturbed if Exon 9 is deleted because the 
cut site overlaps with the Exon 9 region (26).  As a result the PS-1 ΔEx9 mutant 
maintains its full length form and since it is not processed to the commonly found 
active heterodimer, then one would assume that its APP cleavage role would be 
reduced; however, this is not the case as two groups have found that in comparison 
to other mutations the PS-1 ΔEx9 mutant actually generates more fibrillogenic Aβ42 
(36, 116).  Steiner et al  (117) have proposed that this gain-of-function mutation is 
actually a result of the serine to cyteine mutation at the Exon 8/10 junction and not 
the ΔEx9.   
 This mutation has been used by various groups such as Smith et al (118) and 
Cedazo-Minguez et al (102) to show that Ca2+ store concentrations are increased in 
experimental models expressing PS-1 ΔEx9, compared to WT and the former group 
also showed that CCE was suppressed (102, 118). 
 
1.5.1.2 Y115H mutant 
 The PS-1 Y115H mutant was first found by Campion et al (119) who were 
screening for PS-1 gene mutations in 12 different French families with EOAD.  PS-1 
Y115H is a missense mutation that changes the codon TAT to CAT producing a 
histidine instead of a tyrosine amino acid during translation.  This mutation is very 
aggressive as the age of onset, at 35-37 years of age, was the earliest of all families 
screened (119). This same group found the Y115H missense mutation in another 
EOAD family with an age of onset of 36-47 years (120).   
 Not much work has been done with the PS-1 Y115H mutant, but three 
studies that revealed much about PS-1 function, Aβ production and AD will be 
described.  First, it was commonly thought that when PS-1 WT proteins are mutated 
their activity would decrease, but in the case of PS-1 Y115H it actually was more 
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active.  This increased function was discovered when it was observed that N-
terminal truncated Y115H  and C-terminal truncated PS-1 WT are still able to form 
active heterodimers (121).  This fact led to the notion that PS-1 mutations could 
cause an increase, and not necessarily a decrease, in function.  It was then found in 
13 different cell lines and six FAD PS-1 mutations (Y115H, ΔEx9, L392V, H163R, 
M146L and L286V) that the ratio of Aβ42 to total Aβ was the highest for PS-1 ΔEx9 
(age of onset 45-55 years) and third lowest for PS-1 Y115H (age of onset 35-37 
years) (116).  This work illustrated that more Aβ production might not necessarily 
lead to an earlier onset of AD.  Lastly, over-expression of either of the PS-1 mutants 
Y115H, M146V or D257A in a mouse embryonic fibroblast (MEF) cell line that had 
both endogenous PS-1 and PS-2 knocked-out, Kim et al (28) showed that each of 
these mutants could generate different levels of the Notch intracellular domain 
(NICD).  PS-1 M146V produced the highest amount, even higher than WT, and PS-
1 Y115H produced less than WT (28).  The D257A mutant did not generate any 
NICD  (28).  These data provided evidence for different PS-1 missense mutations 
having different cellular effects even though they all lead to familial AD. 
 
1.5.1.3 M146V mutant 
 In contrast to PS-1 Y115H, the PS-1 M146V mutation is used in numerous 
experimental research studies probably because of the former’s lack of clinical 
features and the latter’s abundance.  The PS-1 M146V missense mutation was found 
in families from Finland and Sweden, and the mean age of onset is around 36-40 
years of age (40).  Some of the clinical signs that have a higher incidence in people 
with this mutation compared to sporadic AD are myoclonus, seizures, 
extrapyramidal signs and apraxia (40). 
 Very recently the specific M146V mutation was found to be responsible for a 
significant increase in p75 neurotrophin receptor proteolysis compared to WT PS-1 
(122).  In contrast, the PS-1 ΔEx9 mutant produced a lower amount of p75 
neurotrophin receptor fragments, when compared to WT PS-1.  As this receptor is 
involved in promoting neuronal death and is expressed on basal forebrain 
cholinergic neurons (which very susceptible during AD), then the p75 peptide 
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fragments formed by PS-1 M146V could initiate cell signaling events leading to 
apoptosis (122).  Other reports have found that this mutation does not stimulate 
neurite growth and that it decreases the nuclear translocation of the Notch1 NICD 
(123).  Overexpression of the PS-1 M146V mutant in cells results in an increased 
amount of free Ca2+ (100, 124), but the mechanism involved is not dependent on the 
formation of passive cation channels in the ER as seen with PS-1 WT, D257A and 
ΔEx9 proteins (32).  Also in transgenic PS-1 M146V knock-in mice, there are 
increases in oxidative stress (125) and increases in cytosolic Ca2+ levels compared to 
controls (103, 104, 126). 
 
1.5.1.4 D257A mutant 
 As discussed earlier, PS-1 contains the catalytic core of γ-secretase and this 
catalytic area is an aspartyl protease centered on the amino acids Asp 257 and 385 
(29).  The PS-1 aspartic acid 257 to alanine 257 (D257A) mutant is an artificial 
mutation, on the NTF of PS-1 that, for experimental reasons, is used when a 
theoretically inactive PS-1 is needed.  
 The manner in which the two key aspartic acids of PS-1 interact with each 
other and its substrate(s) is still subject to theory, but one group has provided some 
evidence that aspartic acid 385 is sterically blocked inside and aspartic acid 257 is 
more accessible by facing the outside (28). First it was observed that when PS-1 
D257A and WT PS-1 NTF were co-expressed in PS-1/2 double knockout MEFs, 
Notch could still not be cleaved; however, when PS-1 WT and the D385A 
counterpart, PS-1 CTF, were co-expressed in the same cell line, Notch cleavage was 
reestablished (28).  Furthermore WT PS-1 CTF with PS-1 D385A co- 
immunoprecipitated, but WT PS-1 NTF and PS-1 D257A did not (28).  Altogether, 
their data suggested that unlike the D385A mutant, which cannot freely associate 
with proteins because of its orientation inward, the D257A mutant can easily 
associate with proteins because it faces outward.  
 Concerning PS-1 D257A’s involvement in γ-secretase activity, most people 
uphold Wolfe et al’s (29) idea that this is a dominant negative mutant, even though 
some reports have shown that expression of PS-1 D257A does not reduce the 
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production of Aβ (although Notch cleavage to the NICD is almost always affected) 
(127, 128). 
 
1.5.2 Research objectives 
 All of the just described PS-1 constructs will be used to examine our 
hypothesis that proposes a tri-partite relation between PS-1, MAO-A and Ca2+ in AD.  
The specific aims are: 
 1) To determine if familial AD-associated PS-1 mutations affect intracellular 
Ca2+.  
 2) To determine if over-expression of PS-1 proteins in cells can affect basal 
and Ca2+-sensitive MAO activities. 
  3) To determine if basal and Ca2+-sensitive MAO activities are altered in 
brain tissue homogenates from PS-1 transgenic mice. 
 4) To identify if any change in MAO activity are a result of altered protein 
levels. 
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2 MATERIALS AND METHODS 
 
 
2.1 Materials 
 
 All of the materials and reagents discussed below and in the methods section 
were obtained from each company identified (in brackets) immediately following the 
product or reagent, and the company addresses are listed in Table 2.1. 
 
2.1.1 Vectors 
 Three vectors were used during the course of these experiments; namely 
pcDNA3.1(+), for simple expression (Invitrogen), pCMV/myc/mito, for targeting of 
proteins to the mitochondria (Invitrogen), and pREP, for expressing CB-28K (kindly 
provided by Dr. Allan Pollock, University of California, San Francisco, USA). 
 The pcDNA3.1(+) vector enables a high level of protein expression in 
mammalian cells through its Human cytomegalovirus immediate-early (CMV) 
promoter.  It also has a forward (+) direction Multiple Cloning Site (MCS) to allow 
insertion of the cDNA as well as an Ampicillin resistance gene which facilitates the 
selection of pcDNA3.1(+) positive bacterial colonies during transformations of 
bacterial plasmids and for selection of stable transformants, if needed. The pREP 
and pCMV/myc/mito vectors also have a specific MCS and allow for Ampicillin 
resistance.  
 
2.1.2 Plasmids 
 The cDNAs for PS-1 WT, D257A, Y115H, and Exon 9 deletion (ΔEx9) are 
all subcloned in the pcDNA3.1 vector and were kindly provided by Dr. Georges  
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  Table 2.1: Company name and address 
Company Address 
American type culture collection Manassas, VA, USA 
Amersham Biosciences Piscataway, NJ, USA 
BD Biosciences Mississauga, ON, Canada 
BDH Inc. Toronto, ON, Canada 
Bio-Rad  Hercules, CA, USA 
Cell Signaling Technology, Inc.  Danvers, MA, USA 
CHEMICON International Temecula, CA, USA 
EM Science Inc Gibbstown, NJ, USA 
EMD Biosciences Inc. San Diego, CA, USA 
EMD Chemicals Inc Gibbstown, NJ,USA 
Fermentas Inc Burlington ON, Canada 
GE Healthcare Uppsala, Sweden 
GIBCO-BRL Gaithersburg, MD, USA 
Hyclone Logan, UT, USA 
ICN Biomedicals Aurora, OH, USA 
Invitrogen Carlsbad, CA, USA 
J.T. Baker Phillipsburg, NJ, USA 
MP Biomedicals Solon, OH, USA 
PerkinElmer  Waltham, MA, USA 
Pierce Rockford, IL, USA 
Santa Cruz Biotechnology, Inc Santa Cruz, CA, USA 
Sigma-Aldrich St. Louis, MO, USA 
Stratagene  La Jolla, CA, USA 
The Jackson Laboratory Bar Harbor, ME, USA 
VWR West Chester, PA, USA 
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Lévesque at Laval University, Quebec. WT PS-1 cDNA was used to generate the 
PS-1 M146V mutation. 
 
2.1.3 Competent bacterial cells used for transformation 
 The DH5α E. coli bacterial strain was obtained from American type culture 
collection (ATCC) and was used to make competent cells for plasmid transformation.   
 
2.1.4 Cell lines 
 Cell lines included mouse hippocampal-derived HT-22 cells (kindly 
provided by Dr. P. Maher, The Scripps Research Institute, La Jolla, CA), human 
embryonic kidney (HEK) 293A cells (ATCC) and rat phaeochromocytoma (PC12) 
cells (ATCC).  Both the HT-22 and PC12 cells are neuronal cell lines, and have a 
high MAO-A activity and low MAO-A protein expression; in contrast, HEK 293A 
cells are non-neuronal and have a high MAO-A protein expression but low MAO-A 
activity.  HT-22 and HEK 293A cells are immortalized cell lines while the PC12 cell 
line is derived from a neuroendocrine tumor cell.  Therefore, each cell line was 
applied for a specific use in each experiment. 
 
2.1.5 Antibodies 
  The PS-1 protein was detected using a mouse monoclonal anti-PS-1 loop 
antibody (CHEMICON International).  This antibody recognizes the PS-1 loop near 
the C-terminal of the protein, which spans amino acids 263 to 378, and detects an 
18-20 kDa band on Western blot.  The dilution ratio used, for all membranes, was 1: 
1000.   
 The three MAO antibodies, MAO-A (H-70), MAO-A (T-19) and MAO-B 
(C-17) are from Santa Cruz Biotechnology, Inc.  MAO-A (H-70) binds to C-
terminal amino acid residues 458-527 and is a rabbit polyclonal antibody.  MAO-A 
(T-19) binds to N-terminal amino acid residues and is a goat polyclonal antibody.  
On Western blots, both of these antibodies detect a 61 kDa band.  The MAO-B (C-
17) goat polyclonal antibody recognizes C-terminal amino acid residues on the 
MAO-B protein and detects a 60 kDa band on Western blot.  The antibody MAO-A 
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(H-70) was diluted in a ratio of 1: 250-1000, MAO-A (T-19) was diluted in a ratio 
of 1: 1000 and MAO-B (C-17) was diluted in a ratio of 1: 500-1000.     
 A rabbit polyclonal anti-Calbindin D28K (H-50) (Santa Cruz Biotechnology, 
Inc.) binds to N-terminal amino acids 35-84 on the calbindin protein and detects a 
29 kDa band on Western blot.  The dilution ratio used, for all membranes, ranged 
from 1: 50-250. 
 For detecting activated (phosphorylated) p38 the rabbit polyclonal phospho-
p38 MAP kinase antibody from Cell Signaling Technology, Inc. was used.  This 
antibody recognizes p38 MAP kinase when it is phosphorylated on threonine180 
and tyrosine182.  On Western blots, the phospho-p38 protein migrates as a 43 kDa 
band (presumable due to additional post-translational modification).  Phospho-p38 
MAP kinase antibody was diluted in a ratio of 1: 100.  
 In all Western blots β-actin protein levels were examined to demonstrate 
equal protein loading across lanes (as an internal standard, loading control).  The 
primary mouse monoclonal anti-β-Actin antibody was used (Sigma-Aldrich).  This 
antibody will recognize N-terminal amino acids on the β-actin protein and present as 
a 49 kDa band on Western blot.  The dilution we used for all immunoblots was 
1:3000. 
 When needed, all of the antibodies discussed above were diluted using 5% 
milk in TBS-Tween 20 except the phospho-p38 MAP kinase which was diluted 
using 5% BSA (EMD Chemicals Inc) in TBS-Tween 20.  All primary antibodies are 
stored at -20◦C except for the MAO antibodies and the Calbindin D28K antibody, 
which are stored at 4◦C. 
 
2.1.6 Radioactivity  
 The protocols, radioactive work areas and equipment involved in the use of 
radioactive substances followed the University of Saskatchewan’s Radiation Safety 
Code and were approved by Radiation Safety Advisory Committee.  The nuclear 
substance permit (NPR-05-U) was obtained from the Radiation Safety Protocol 
Approval Committee.  For this project all [14C]-radiolabelled substances were 
obtained from PerkinElmer. 
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 2.1.7 Mice 
 All of the handling, care, housing and experiments involving mice followed 
the guidelines from the Canadian government’s Canadian Council on Animal Care.  
In addition each procedure was approved by the University of Saskatchewan’s 
Committee on Animal Care and Supply.  Mice were purchased from Jackson Labs 
(The Jackson Laboratory). 
 
 
2.2 Methods 
 
2.2.1 Competent cell preparation 
a. Incubate one colony of DH5α E. coli bacteria (ATCC) with 5 ml Double Yeast 
Tryptone (DYT) solution (16 g BactoTM Tryptone, BD Biosciences; 10 g 
BactoTM Yeast extract, BD Biosciences; 5 g NaCl, EMD Chemicals Inc; 1000 
ml ddH2O, pH 7.0, autoclaved) overnight at 37◦C in a bacteria shaker. 
b. Combine 2 ml of above solution with 100 ml SOB (950 ml ddH2O, 20 g 
BactoTM Tryptone, BD Biosciences; 5 g BactoTM Yeast extract, BD Biosciences; 
0.5 g NaCl, EMD Chemicals Inc) and incubate at 37◦C while shaking until the 
optical density (OD) of 0.45 is achieved. 
c. Equally separate the solution into four 50 ml autoclaved centrifuge tubes and 
store on ice for 10 min. 
d. Centrifuge the tubes at 2500 rcf for 10 min at 4◦C and remove the supernatant 
carefully. 
e. Add 8 ml of pre-chilled transformation buffer (15 mM CaCl2, BDH Inc.; 250 
mM KCl, BDH Inc; 10 mM 1,4-Piperazine Diethane Sulfonic Acid, Sodium 
Salt (PIPES), EMD Chemicals Inc; 55 mM MnCl2, EMD Chemicals Inc; pH 6.7) 
to each tube to resuspend the cells and store on ice for 10 min. 
f. Centrifuge the tubes at 2500 rcf for 10 min at 4◦C and remove the supernatant 
carefully. 
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g. Add 2 ml of pre-chilled transformation buffer to each tube to resuspend the 
cells. 
h. To each tube slowly add enough DMSO (EM Science Inc) to have a total of 7% 
DMSO and store on ice for 10 min. 
i. On dry ice, aliquot 50-100 µl into pre-chilled and autoclaved microcentrifuge 
tubes. Store at -70◦C. 
 
2.2.2 Transformation 
 Amplification of plasmid DNA is carried out using bacterial competent cells.  
This method involves taking a plasmid or vector which contains a specific DNA 
construct and inserting it into a bacterial cell through its membrane pores.  The 
bacteria cell will then duplicate this plasmid when it undergoes replication.  The 
transformation protocol is as follows: 
a. Pre-chill all Falcon® polypropylene tubes (BD Biosciences) on ice. 
b. Remove the bacterial cells (DH5α competent E.coli cells) from the -70◦C 
freezer and thaw on ice. 
c. Once thawed, combine 1-2 µl of DNA and a 50 µl aliquot of DH5α cells in the 
Falcon® tube. 
d. Keep mixture on ice for 30 min. 
e. Place the Falcon® tube with the mixture in a 42◦C water bath for 30 sec to heat 
shock the bacterial cell membrane. 
f. Place the tube on ice for 2 min again to help the bacterial cell membrane 
recover. 
g. Add 250 µl of SOC medium to the Falcon® tube. 
a) For 1 ml SOC Medium: 
i. Work at all times near an open flame. 
ii. Add 975 µl SOB (950 ml ddH2O, 20 g BactoTM Tryptone, BD Biosciences; 
5 g BactoTM Yeast extract, BD Biosciences; 0.5 g NaCl, EMD Chemicals) 
to a microcentrifuge tube. 
iii. Add to the tube 5 µl of 2 M MgCl2 (EM Science Inc) and 20 µl 1 M 
glucose (BDH Inc). 
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h. Shake the tube for 30 min at 37◦C to help the bacteria grow. 
i. While waiting for 30 min remove agar plates from 4◦C fridge and place in 
incubator to warm up the agar.  This helps the DNA/bacteria solution to absorb. 
a) Preparation of agar plates: 
i. Combine DYT solution (16 g BactoTM Tryptone, 10 g BactoTM Yeast 
extract, 5 g NaCl, 1000 ml ddH2O, pH 7.0, autoclaved) with 15 g of 
BactoTM Agar (BD Biosciences). 
ii. Depending on the selection gene expressed in the plasmid, add either the 
ampicillin (EMD Biosciences Inc.) or kanamycin (Sigma-Aldrich) 
antibiotic in a 1: 1000 ratio of antibiotic to DYT/agar solution. 
iii. Working near a flame, pour the solution into Petri dishes and flame the 
top of the solution for a couple seconds to get rid of the air bubbles. 
iv. Keep at room temperature for a couple hours for the agar to solidify. 
v. Store agar plates upside down in a 4◦C fridge. 
j. Using all ethanol (EMD Chemicals Inc) sterilized tools and near an open flame 
plate 4 µl, 20 µl and 100 µl of the DNA/bacteria solution on three separate agar 
plates. 
k. Place the plates in a 37◦C incubator for16-20 hours. 
l. Agar plates with antibiotic can be stored at 4◦C for approximately one month.   
 
2.2.3 Mutagenesis  
 The PS-1 plasmids were obtained from Dr. Georges Lévesque at Laval 
University.  Only the PS-1 M146V mutant had to be generated.  This was done using 
the QuikChange® Site-Directed Mutagenesis Kit from Stratagene. 
 Two primers (forward and reverse) were designed according to the 
manufacturer’s suggestions.  The PS-1 wild-type sequence from the National Center 
for Biotechnology Information (NCBI) GenBank, was analyzed and the forward 
primer was chosen to be 5′-C ATG ATC AGT GTG ATT GTT GTC GTG ACT 
ATC CTC CTG GTG GTT C-3′.  Consequently the reverse primer was then: 5′-G 
AAC CAC CAG GAG GAT AGT CAC GAC AAC AAT CAC ACT GAT CAT G-
3′.  These primers are 44 base pairs long, have a Tm (melting temperature) of 81.2◦C, 
35 
a %GC of 48 and the single point mutation is in the middle, which follows the 
primer criteria in the Stratagene manual.  Once the sequence was chosen, the primers 
(Invitrogen) were diluted with ultrapure H2O and stored at -20◦C.  The following 
specific polymerase chain reaction (PCR) procedure was carried out: 
a. To an autoclaved PCR tube add the reagents below in the amounts specified: 
 5 µl 10X Reaction buffer 
 2 µl DNA template (50 ng) 
 1 µl Forward primer (125 ng/µl) 
 1 µl Reverse primer (125 ng/µl) 
 1 µl dNTP mix 
 40 µl ddH2O 
(All above reagents, with the exception of the primers, are from Stratagene and 
all are stored at -20◦C) 
b. Vortex the tube, then add 1 µl of 2.5 U/µl PfuTurbo® DNA polymerase 
(Stratagene).  
c.  Vortex again and briefly tap the tube so all solution is at the bottom. 
d. Place the samples in a thermal cycler and use the following program: 
 First stage:  1 cycle at 95◦C for 30 sec. 
 Second stage:  16 cycles of: 1) Denature step: 95◦C for 30 sec 
                                                      2) Anneal step: 55◦C for 60 sec 
                                                      3) Extension step: 68◦C for 7 min  
e. Immediately place the tubes on ice for 2 min. 
f. To each tube add 1 µl of 10 U/µl Dpn I (Stratagene) and mix with the pipet tip. 
(The Dpn I enzyme will digest all parental methylated DNA).  
g. Briefly spin down the tube and incubate each tube for 1 hour at 37◦C. 
h. Pre-chill all Falcon® polypropylene tubes (BD Biosciences) on ice. 
i. Remove the bacterial cells (use XL1-Blue supercompetent cells (Stratagene)) 
from the -70◦C freezer and thaw on ice. 
j. Once thawed, combine exactly 1 µl of DNA to each 50 µl aliquot of XL1-Blue 
supercompetent cells in the Falcon® tube. 
k. Keep mixture on ice for 30 min. 
l. Place the Falcon® tube with the mixture in a 42◦C water bath for 45 sec to heat 
shock the bacterial cell membrane. 
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m. For 2 min place the tube on ice again to help the bacterial cell membrane 
recover. 
n. Add 500 µl of preheated (42◦C ) NZY+ medium (10 g NZ amine casein 
hydrolysate, Sigma-Aldrich; 5 g BactoTM Yeast extract, BD Biosciences; 85.5 
mM NaCl, EMD Chemicals Inc; 12.5 mM MgCl2, EMD Chemicals Inc; 12.5 
mM MgSO4, EMD Chemicals Inc; 20 mM glucose, BDH Inc.; pH 7.5). 
o. Shake the tube for 1 hour at 37◦C to help the bacteria grow. 
p. To plate the bacteria, complete steps i-l from the transformation protocol in 
section 2.2.2.  The only exception is in step 2.2.2.j. it is necessary to plate 100 
µl and 250 µl of the DNA/bacteria solution. 
 
2.2.4 Maxi-prep 
 A maxi-prep is the process of amplifying and purifying plasmid DNA on a 
large scale.  The general procedure involves growing a bacterial culture, then 
harvesting and lysing the bacteria, and finally purifying the plasmid DNA.  The 
method is as follows: 
a. Growing the bacteria: 
a) To a 14 ml round-bottom polypropylene test tube add 4.5 ml of Terrific 
broth (TB) (12 g BactoTM Tryptone, BD Biosciences; 24 g BactoTM Yeast 
extract, BD Biosciences; 4 ml glycerol, MP Biomedicals; 900 ml ddH2O; 
autoclaved) and 0.5 ml of 0.17 M Potassium Phosphate Monobasic 
(KH2PO4) (J.T. Baker) /0.72 M Potassium Phosphate Dibasic (K2HPO4) (J.T. 
Baker). 
b) Add the appropriate antibiotic in a 1: 1000 (antibiotic: solution) ratio. 
c) Near a Bunsen burner flame use an autoclaved pipette tip to pick up a single 
freshly isolated transformed bacteria colony from the agar plate. 
d) Incubate the test tube in a shaker/incubator for 6 hours at 37◦C. 
e) After 6 hours, combine the bacteria solution with 270 ml of TB and 30 ml 
0.17 M KH2PO4 / 0.72 M K2HPO4 to a 1 L conical flask near an open flame. 
f) Add the proper antibiotic in a 1: 1000 (antibiotic:solution) ratio to the 
conical flask. 
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g) Shake the conical flask in a bacteria shaker for 16-20 hours at 37◦C. 
b. Harvesting and lysing the bacteria: 
a) The next day take out and mix 850 µl of bacteria culture and 150 µl sterile 
glycerol (autoclaved) in a 1 ml cryogenic vial.  Store this in a -70◦C freezer 
for future use.  
b) Split the rest of the 300 ml bacteria culture into two 250 ml centrifuge 
bottles. 
c) In a centrifuge, spin at 4000 rpm for 15 min at room temperature (20◦C). 
d) Take out the supernatant and re-suspend the two pellets with 50 ml of cold 
STE (0.1 M NaCl, EMD Chemicals Inc; 10 mM Tris (base), pH 8.0, J.T. 
Baker; 1 mM EDTA, pH 8.0, EMD Chemicals Inc; store at 4◦C). 
e) Spin the centrifuge bottles again at 4000 rpm for 15 min at room 
temperature (RT) (20◦C). 
f) Remove the supernatant and add 10 ml solution I (50 mM Glucose, BDH 
Inc; 10 mM EDTA, pH 8.0; 25 mM Tris (base), pH 8.0) to each bottle to re-
suspend the pellet. 
g) Combine the two bottles and gently mix in 40 ml solution II (0.2 N NaOH, 
VWR; 1% sodium dodecyl sulfate (SDS), ICN Biomedicals).  Keep at RT 
(20◦C) for 5-10 min. 
h) Then add to the bottle 20 ml of the acidic solution, solution III (300 ml 5 M 
Potassium Acetate, EMD Chemicals Inc; 57.5 ml Glacial Acetic Acid, BDH 
Inc; 142.5 ml ddH20) and mix well.  Keep on ice for 5 min. 
i) Centrifuge for 15 min at 4000 rpm at RT. 
j) Filter the supernatant through 4 layers of cheese-cloth into a clean 250 ml 
centrifuge bottle. 
k) Add isopropanol (EMD Chemicals Inc) in the amount equal to 60% of the 
total filtered supernatant volume.  Keep at RT for 10-30 min. 
l) Centrifuge for 15-30 min at 5000 rpm at RT. 
m) Take out the supernatant and carefully add some 85% ethanol (EMD 
Chemicals Inc) to the pellet to wash it. 
38 
n) Remove ethanol (let air dry) and liquefy the pellet with 3 ml T.E. (10 mM 
Tris (base), pH 8.0; 1 mM EDTA, pH 8.0). 
c. Purification of the plasmid DNA: 
a) Pour the dissolved pellet into a 50 ml polypropylene test tube and mix in 4.8 
ml of ice-cold 5 M lithium chloride (J.T. Baker, store at 4◦C). 
b) Centrifuge the tube for 10 min at 10000 rpm at RT. 
c) Transfer the supernatant to another 50 ml polypropylene test tube and add to 
it the same volume of ispropanol. Vortex and keep at RT for 5 min. 
d) Centrifuge the tube again for 10-20 min at 10000 rpm at RT. 
e) Take out the supernatant and add 85% ethanol to rinse the pellet. 
f) Remove all ethanol and add 500 µl T.E to dissolve the pellet.  Then add 5 µl 
Ribonuclease A (10 mg/ml, Fermentas Inc).  Keep at RT for 30 min. 
g) After 30 min, mix in 400 µl of 1.6 M NaCl/13% (w/v) polyethlyene glycol 
(PEG) (EM Science Inc) (100 ml 1.6 M NaCl, 13 g PEG) and transfer the 
solution to a microcentrifuge tube. 
h) Vortex and then centrifuge for 2 min at 12000 rcf at 4◦C. 
i) Discard the supernatant and resuspend the pellet in 500 µl T.E to dissolve. 
j) In a fumehood, add 500 µl phenol (EMD Chemicals Inc). Then vortex and 
centrifuge at 5000 rpm for 5 min at RT. 
k) Remove the top aqueous layer to another microcentrifuge tube.  
l) Repeat the above 2 steps. 
m) In a fumehood, add 500 µl chloroform (BDH Inc).  Then vortex and 
centrifuge at 5000 rpm for 5 min at RT. 
n) Remove the top aqueous layer to another eppendorf tube. 
o) Add enough 5 M NaCl for a final concentration of approximately 125 mM. 
p) Mix in two volumes of 400 µl cold 100% ethanol and incubate on ice for 
10-30 min. 
q) Centrifuge for 5 min at 12000 rcf at 4◦C. 
r) Discard the supernatant and add 200 µl of 85% ethanol.  Vortex and 
centrifuge for 2 min at 12000 g at 4◦C. 
s) Remove all ethanol and dissolve the pellet in 300-1000 µl ultrapure H2O. 
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t) Store DNA in 1 µg/µl concentrations at -20◦C. 
 
2.2.5 Transfection of cells 
 Transfection of DNA into a mammalian cell allows the cells to transiently 
over-express the corresponding protein.  Transfection is performed as follows:  
a. 24 hours before transfection, plate 3x106 cells in each 100 mm cell culture dish 
in 7.5 ml of the appropriate cell growth medium – for HT22 cells, this would be 
a medium of 10% Fetal Bovine Serum (FBS) (GIBCO-BRL) in Dulbecco’s 
Modified Eagle’s Medium (DMEM)/Low glucose (Hyclone). 
b. At the time of transfection, add the plasmid DNA (the DNA: LipofectamineTM 
2000 ratio should be 1.5 µg: 2.5 µl) and 60 µl LipofectamineTM 2000 
(Invitrogen) to separate autoclaved microcentrifuge tubes containing 1500 µl of 
DMEM/Low glucose.  Vortex gently. 
c. Incubate at RT (20◦C) for 4-5 min. 
d. Combine the plasmid DNA solution with the LipofectamineTM 2000 solution 
and vortex gently.  
e. Incubate at RT for 20 min. 
f. After 20 min, add the solution to side of each cell culture dish containing the 
medium and adhered cells. Rock the dish back and forth to distribute the 
solution evenly. 
g. After 4-6 hours replace the medium with new growth medium. 
h. Incubate the cells for 24-48 hours in a cell culture incubator (37◦C, 5% CO2).  
 In order to use these transfected cells for various assays, the cells from each 
cell culture dish are first harvested by removing the growth medium and adding 
Trypsin-EDTA solution (Sigma-Aldrich) (1 ml/100 mm cell culture dish) for 1 min 
at 37◦C and then collected with cell growth medium and 1X PBS (Phosphate 
buffered saline) (8 g NaCl, EMD Chemicals Inc; 0.2 g KCl, BDH Inc; 1.44 g 
Na2HPO4, EMD Chemicals Inc; 0.24 g KH2PO4, J.T. Baker; 1000 ml ddH20; pH 
7.4).  After collecting the cells they are centrifuged at 1000 g for 5 min at 4◦C, and 
the supernatant is removed.  The pellet is washed 3 times by first re-suspending with 
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1X PBS and centrifuging at 1000 g for 5 min at 4◦C, then aspirating the 1X PBS.  
The resulting cell pellet can be used immediately for experiments.  
 
2.2.6 Immunoprecipitation 
 Immunoprecipitation is used to determine if a protein physically interacts 
with other proteins.  Either protein A or protein G sepharose bead solutions are used 
to pull down the protein of interest, and any associated protein(s).  Western Blot 
technique (discussed in the next section) is used to detect the associated proteins.  
The general procedure for immunoprecipitation is as follows: 
a. Freshly harvest cells (harvesting protocol is described in the final paragraph of 
section 2.2.5) from, at minimum, one 90% confluent 100 mm cell culture dish 
per sample. 
b. Re-suspend the entire cell pellet with a proper amount (first try a total volume 
of 100 µl) of Lysis buffer (1% Triton®- X 100, Sigma-Aldrich; 20 mM Tris, 
ICN Biomedicals, pH 7.5; 10% glycerol, MP Biomedicals; 1 mM EDTA, EMD 
Chemicals Inc) and 100X protease inhibitor cocktail (Sigma-Aldrich).  Incubate 
on ice for 30 min. 
c. Centrifuge for 10-20 min at 16000 g at 4◦C. 
d. Determine the total protein concentration for each cell lysate with the BCATM 
protein assay kit (Pierce).  The standards used were bovine serum albumin 
(BSA) protein standards which are included in the kit. 
e. For obtaining a total cell lysate (TCL) sample: 
a) Aliquot out enough supernatant to obtain at least 40 µg protein per sample 
and prepare a 1 µg/µl TCL sample using 4X Loading buffer (2 ml 1 M Tris, 
pH 6.8; 4 ml glycerol; 2 ml 2-mercaptoethanol, EM Science Inc; 30 mg 
bromphenol blue, Sigma-Aldrich; 800 mg SDS, ICN Biomedicals; 10 ml 
ddH20) and Lysis buffer. 
b) Boil all samples for 5 min at 95◦C and store at -20◦C. 
f. With the rest of the cell lysate supernatant (a minimum of 300 µg of protein is 
needed for each immunoprecipitation), add the specific amount of primary 
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antibody in the ratio recommended (if no ratio is specified then try 1 µg 
antibody: 100 µg protein). 
g. Rock the microcentrifuge tubes on their side overnight at 4◦C. 
h. The next morning, add 50 µl protein sepharose A (GE Healthcare) (generally 
used for polyclonal antibodies) or protein sepharose G (GE Healthcare) 
(generally used for monoclonal antibodies) to the microcentrifuge tubes. 
i. Rock the tubes, on their side, for 1 hour at 4◦C. 
j. Centrifuge the tubes at 10 000 g for 5 min at 4◦C. 
k. Check if all pellets are equal in size. If not equal, add more of the protein 
sepharose A or G used in step h and repeat steps i and j. 
l.  If all pellets are equal, to obtain a supernatant sample repeat all directions 
under step e. 
m. If a supernatant sample is not required, carefully aspirate all of the 
supernatant without touching the pellet. 
n. Re-suspend the pellet in 500 µl of lysis buffer and briefly vortex. 
o. Centrifuge all tubes at 10 000 g for 5 min at 4◦C. 
p. Carefully, aspirate all of the supernatant without touching the pellet. 
q. Repeat steps n through p two more times. 
r. Add 20-25 µl of 1X loading buffer to each tube and mix by tapping the tube 
gently. 
s. Boil all tubes for 5 min at 95-100◦C and store at -20◦C. 
t. When ready to use the sample, centrifuge all tubes at 10 000 g for 5 min at 
room temperature. 
 To determine if proteins interact, then the Western blot protocol, explained in 
the next section, is used (simply begin at step b).  The only exception is at the time 
of loading the sample into the stacking gel well, load only the supernatant and not 
any of the sepharose beads.  Also when running the gel (step 2.2.7.b.d: transferring 
proteins to a gel), it may be necessary to run for approximately 30 min – 45 min 
longer than the usual Western blot time if the molecular weight of the protein of 
interest is similar to the antibody heavy chain molecular weight that is around 50 
kDa. This will allow for better resolution of the two bands. 
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 2.2.7 Western blot (Immunoblot) 
 The Western blot or immunoblot assay is used for the qualitative comparison 
of protein levels.  Equal amounts of total protein extracts from tissue or cell samples 
are loaded onto a gel and they migrate according to molecular weight (MW); the 
smaller the protein is the smaller the MW, so it will migrate faster.  Similarly, the 
larger the protein, the slower it will migrate.  The specific proteins are detected by 
specific antibodies, which are, in turn, detected by secondary antibodies conjugated 
with horseradish peroxidase.  Incubation with a chemiluminescent substrate allows 
for an image of the protein band to be detected on a film.    
 There are four main parts to Western Blot assay:  Denaturing the three- 
dimensional proteins to linear proteins, loading the proteins onto a gel, transferring 
them to a membrane and then visualizing the proteins on film.   
a. Denaturing proteins to linear proteins: 
a) Take harvested cells (harvesting protocol is found in the end paragraph of 
section 2.2.5) or tissue, and lyse – tissue should be homogenized then lysed 
- with the appropriate amount of Lysis buffer (1% Triton®- X 100, Sigma-
Aldrich; 20 mM Tris, ICN Biomedicals, pH 7.5; 10% glycerol, MP 
Biomedicals; 1 mM EDTA, EMD Chemicals Inc) and 100X protease 
inhibitor cocktail (Sigma-Aldrich).  Incubate on ice for 30 min. 
b) Centrifuge for 10-20 min at 16000 rcf at 4◦C. 
c) Determine the total protein concentration for each cell lysate with the 
BCATM protein assay kit (Pierce).  
d)  Prepare equal protein concentrations of 1-2 µg/µl using 4X Loading buffer 
(2 ml 1 M Tris, pH 6.8; 4 ml glycerol; 2 ml 2-mercaptoethanol, EM Science 
Inc; 30 mg bromphenol blue, Sigma-Aldrich; 800 mg SDS, ICN 
Biomedicals; 10 ml ddH20) and Lysis buffer. 
e) Boil all samples for 5 min at 95◦C and store at -20◦C.   
b. Transferring proteins to a gel: 
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a) Following the amounts shown below prepare an SDS-PAGE gel, which has 
a 10% resolving gel (bottom layer of the gel) and 4% stacking gel (top layer 
of the gel).  (NB:  The amounts listed below are for a 1 mm thick gel.) 
 10% Resolving gel (10 ml) 4% Stacking gel (5 ml) 
ddH2O      4.01 ml   ddH2O  3.00 ml  
Buffer A      2.50 ml   Buffer C  1.25 ml  
Acrylamide    3.33 ml   Acrylamide  0.67 ml  
10% APS      50 μl   10% APS  25 μl  
10% SDS      100 μl   10% SDS  50 μl  
TEMED      10 μl   TEMED   5 μl   
Buffer A: 18.45 g Tris-HCL, ICN Biomedicals; 77 g Tris  (base), J.T. 
 Baker; 2 g SDS; 50 0ml H2O; pH 8.8   
Buffer C: 30 g Tris (base), 2 g SDS, 500 ml H2O, pH 6.8  
10% Ammonium persulfate (APS): 1 g APS, Invitrogen, 10 ml H2O 
10% Sodium dodecyl sulfate (SDS): 1 g SDS, 10 ml H2O 
(TEMED and Acrylamide are from Bio-Rad and are stored at 4◦C, 10% APS 
is stored at -20◦C, and Buffer A, Buffer C and 10% SDS are stored at RT)  
b) To the gel apparatus, add 1X Running buffer from a 10X Running buffer 
stock (30.3 g Tris (base); 144 g glycine, MP Biomedicals; 10 g SDS, 1000 
ml H2O). 
c) In the first well load a broad range protein ladder (3 µl in 1X Loading buffer) 
(PageRuler™ Prestained Protein Ladder Plus, Fermentas Inc), then load 
each well with an equal volume of sample (sample preparation was 
discussed in section 2.2.7.a) ranging from 10 µl – 40 µl of sample per well.  
d) Set apparatus to a constant voltage of 100 - 115 Volts (V) and run for the 
suitable amount of time.  
c. Transferring proteins from a gel to a membrane: 
a) First sandwich the gel and a pure Nitrocellulose membrane (Bio-Rad) 
between two filter papers (Bio-Rad) and roll out the bubbles.  Then place 
everything between two filter pads and put in the appropriate holder. 
b) Pour in 1X Transfer buffer (3 g Tris (base), 14.4 g glycine, 37.5 mg SDS; 
200 ml methanol, EMD Chemicals Inc; 800 ml H2O) and set the apparatus 
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to 230 mA.  Transfer for the suitable amount of time and make sure to add 
an ice pack inside the apparatus and constantly stir the 1X Transfer buffer. 
d. Visualization of protein bands: 
a) Prepare 15-20 ml of 5% milk (instant skim milk powder) in 1X TBS 
solution (from a 10X TBS stock solution: 30 g Tris (base); 80 g NaCl, EMD 
Chemicals Inc; 1000 ml H2O, pH 7.4) and rock the membrane in this 
solution for 1 hour at RT to block it. 
b) Prepare 5 ml of 5% milk in TBS- Tween® 20(T) solution (500 µl Tween® 20, 
EM Science Inc per 1000 ml TBS).  Add the primary antibody to this 
solution in the recommended ratio.   
c) Put the membrane with antibody solution in a sealed bag with no air bubbles 
and place between two glass plates. 
d) Rock overnight at 4◦C. 
e) The next morning remove the primary antibody (antibody solution can be 
re-used, for up to one month, by adding 10% sodium azzide and storing at 
4◦C) and wash the membrane with TBS-T for 10 min on a rocker. 
f) Repeat the wash 2 more times. 
g) Prepare 15 – 20 ml of 5% milk in TBS-T and add the secondary antibody in 
the recommended ratio. 
h) Add the secondary antibody solution to the membrane and rock for 1 - 2 
hours at RT. 
i) Discard the secondary antibody and wash with TBS-T for 10 min on a 
rocker. 
j) Repeat the wash 2 more times. 
k) Combine enhanced chemiluminescent ECL Detection reagent 1 and 
Detection reagent 2 (Amersham Biosciences) in equal volumes and vortex. 
l) Incubate the membrane for 1 min in ECL and then immediately place the 
membrane in a light-proof cassette. 
m) In a dark room, place HyperfilmTM (High performance chemiluminescence 
film, Amersham Biosciences) on top of the membrane (membrane is 
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covered by a thin transparent plastic cover), in the cassette, and wait for the 
necessary amount of time. 
n) Develop the film using a developer machine. 
 
2.2.8 Monoamine oxidase activity assay 
 The Monoamine Oxidase (MAO) activity assay estimates the enzymatic rate 
of conversion of monoamines to aldehydes by MAO.  This assay specifically uses 
the [14C]-radiolabelled monoamine substrates serotonin (5-HT) and 
phenylethylamine (PEA) to measure the activity of MAO-A and MAO-B, 
respectively.  Generally, the protocol is as follows:    
a. Bubble oxygen through potassium phosphate buffer (181.6 ml 1 M K2HPO4, 
18.4 ml 1 M KH2PO4, 1000 ml H2O, pH 7.85, both compounds are from J.T. 
Baker) for 30-45 min at RT. 
b. After the buffer is saturated with oxygen, add 1000 µl- 15000 µl of potassium 
phosphate buffer to the cells and break the cells – or in the case of brain tissue, 
homogenize then break the cell tissue - with 10 plunges of a 1 ml syringe (22 
gauge needle). 
c. Determine the total protein concentration for each sample with the BCATM 
protein assay kit (Pierce).   
d. Make each sample have the same protein concentration of 1-2 µg/µl using the 
oxygen saturated potassium phosphate buffer to dilute the more concentrated 
samples. 
e. Add 50 µl of cell or tissue homogenate to each 1.5 ml microcentrifuge tube and 
keep on ice.  (NB: each sample has at least one blank and one test sample done 
in triplicates). 
f. Prepare all solutions below if required for the particular experiment: 
a) If measuring MAO-A activity, radiolabeled serotonin substrate is made as 
follows (in an authorized radioactive work area):  
i. To make, for example, 3500 µl of 1X total serotonin (5-HT) substrate, 
combine 17.5 µl Hydroxytryptamine binoxalate, 5-[2-14C]- (hot 5-HT 
stock) from PerkinElmer at a specific activity of 48.9 mCi/mmol with 
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17.5 µl of 98.0 mM 5-Hydroxytryptamine hydrochloride (cold 5-HT stock) 
from Sigma-Aldrich (hot to cold stock is in a 1: 1 ratio as determined by 
the specific activity) and 3465 µl oxygen saturated potassium phosphate 
buffer. 
b) If measuring MAO-B activity, radiolabeled PEA substrate is made as 
follows (in an authorized radioactive work area): 
i. To make, for example, 3500 µl of 1X total PEA substrate, combine 3.5 µl 
PEA hydrochloride, β-[ethyl-1-14C]- (hot PEA stock) from PerkinElmer at 
a specific activity of 43.8 mCi/mmol with 31.5 µl of 10.9 mM  
phenethylamine hydrochloride from Sigma-Aldrich (hot to cold stock is in 
a 1: 9 ratio as determined by the specific activity) and 3465 µl of oxygen 
saturated potassium phosphate buffer. 
c) For 1 mM Ca2+ and lesser concentrated Ca2+ solutions: 
i. First make a 100 mM Ca2+ solution (100X Ca2+ working stock) by adding 
3.68 mg Ca2+ chloride dehydrate (BDH Inc) to 250 µl ddH2O. 
ii. For all subsequent 100X Ca2+ working solutions dilute the 100 mM Ca2+ 
stock by half to get the required concentration.  
d) For 1 mM DAPT and lesser concentrated DAPT solutions: 
i. First make a 10 mM DAPT (10X working stock solution) by adding 0.35 
mg DAPT (Sigma-Aldrich) to 80 µl DMSO (EM Science Inc). 
ii. For all subsequent 10X Ca2+ working solutions dilute the 10 mM DAPT 
by the appropriate amount to get the required concentration. 
g. Working in an authorized radioactive work area and with designated equipment, 
incubate the first sample (at least 3 sample tubes) with either Ca2+ or DAPT for 
20 min at RT. 
h.  After 10 min, incubate the second sample (at least 3 sample tubes) with either 
Ca2+ or DAPT for 20 min. 
i. At the end of 20 min for the first sample, add 10 µl of HCL (hydrochloric acid, 
BDH Inc) to at least 3 other sample tubes, from the first sample, selected to be 
the blank. 
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j. Place all of the first sample’s tubes in a 37◦C water bath and add 50 µl of 
radiolabelled substrate, either 5-HT or PEA, to each tube in a consecutive 
manner.  Keep in the water bath for 10 min. 
k. After 10 min, add 10 µl of HCL to all tubes except for the blank tubes in the 
exact order the radiolabelled substrate was added. 
l. Immediately after, take the first sample’s tubes out of the water bath and in a 
fume hood, add 1000 µl of H20 saturated ethyl acetate (BDH Inc)/ toluene 
(EMD Chemicals Inc) (1: 1) solution. 
m. Right after, repeat step i and j for the second sample. 
n. While the second sample is incubating in the water bath, vortex all of the first 
samples for a couple seconds and centrifuge at the highest speed for 30 sec at 
RT. 
o. Take out 700 µl of the top layer of each sample tube and put into a liquid 
scintillation vial. 
p. To each vial, add 4 ml of liquid scintillation fluid (ACS Scintillation Cocktail, 
Amersham Biosciences), cap the vial and put in a vial holder. 
q. Once 10 min have passed for the second sample then repeat steps k-l and then 
n-p for the second sample. 
r. Repeat the entire procedure from steps g-q, if there are more than 2 different 
samples. 
s. Once all samples have been placed in the vials and into the vial holder, add 50 
µl of radiolabelled substrate and 4 ml of liquid scintillation fluid, to be able to 
measure total activity. 
t. Also wipe test at least 3 different areas, with swipe pads, and place in a vial 
with 4 ml of liquid scintillation fluid. 
u. Measure the activity in a liquid scintillation counter machine. 
 
2.2.9 Fluorescent measurements using Fluo-3AM or DCFDA 
 Fluo-3AM allows for the detection of free intracellular Ca2+ levels and DCF 
detects reactive oxygen species.  Both Fluo-3AM and DCFDA are able to pass into 
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the cell where either it binds to Ca2+ or undergoes oxidation, respectively, and 
fluoresces. 
 All of the necessary PS-1 plasmids discussed in section 2.1.2 were 
transfected into HT-22 cells, following the protocol in section 2.2.5, and the level of 
fluorescence was observed by a confocal laser fluorescent microscope.  The only 
exception to the transfection protocol was that a 12-well cell culture dish , instead of 
a 100 mm cell culture dish, was used and the cells were seeded and grown on a 
circular coverslip.  After, the next steps were carried out: 
a. Remove the cell growth medium and wash cells once with 1X PBS (8 g NaCl, 
EMD Chemicals Inc; 0.2 g KCl, BDH Inc; 1.44 g Na2HPO4, EMD Chemicals 
Inc; 0.24 g KH2PO4, J.T. Baker; 1000 ml ddH20; pH 7.4). 
b. Carefully cover the cells with about 150-200 µl of the Fluo-3AM or DCFDA 
solution. 
a) The Fluo-3AM solution is prepared by combining equal volumes of Fluo-
3AM (Invitrogen) and pluronic F-127 (Invitrogen), and then adding this 
solution to 1X Hanks balanced salt solution for neurons (GIBCO-BRL) to 
make a final working concentration of 4 µM of Fluo-3AM/pluronic F-127 
solution. 
b) The DCFDA solution is prepared by combining a 100 µM DCFDA stock 
solution (250 mg DCFDA (Invitrogen) in 10% H20 and 90% DMSO (EM 
Science Inc)) with 1X Hanks balanced salt solution for neurons to make a 
final working concentration of 10 µM DCFDA. 
c. Cover the cell culture dish with tin foil and incubate the cells for 30 min at 37◦C 
and 5% CO2. 
d. Once 30 min has passed, gently wash the cells two times with 1X PBS. 
e. Add 1-2 drops of 1XPBS on a rectangular coverslip and place the cell side of 
the circular coverslip on top of the 1XPBS. 
f. Immediately observe the fluorescence with a confocal microscope set at an 
excitation wavelength of approximately 488 nm (Fluo-3AM) or 493 nm 
(DCFDA) and emission wavelength at 530 nm (Fluo-3AM) or 522 nm 
(DCFDA). 
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 2.2.10 Genotyping of transgenic mice  
 There are two steps of genotyping transgenic mice. A “tail snip” is first 
digested, allowing for the extraction of genomic DNA, and then subjected to PCR. 
a. Tail snip or tissue digestion: 
a) Heat a water bath to 55◦C and a heat block to 100◦C. 
b) If the tail snip or tissue was stored at -20◦C then leave them at RT for at least 
30 min. 
c) In an autoclaved microcentrifuge tube add 2 µl/sample of Proteinase K (20 
mg/ml, Fermentas Inc) and 20 µl/sample of Extraction buffer (50 mM Tris-
HCL, pH 8.0, ICN Biomedicals; 20 mM NaCl, EMD Chemicals Inc; store at 
RT).  Vortex and centrifuge briefly. 
d) Add 22 µl of the solution above into each autoclaved microcentrifuge tube 
containing the thawed tail snip or tissue section. 
e) Vortex for 2 sec and centrifuge for 3 sec at 12,000 rpm. 
f) Digest the tissue in the 55◦C water bath for 15 min. 
g) Vortex for 2 sec and centrifuge for 3 sec at 12,000 rpm. 
h) For a second time, digest the tissue in the 55◦C water bath for 15 min. 
i) If the tissue is not completely digested then repeat steps g and h. 
j) Add 70-178 ml of ddH20 to each tube.  Vortex for 2 sec and centrifuge for 3 
sec at 12,000 rpm. 
k) Boil the tubes for 5 min in a 100◦C heat block to inactivate the Proteinase K. 
l) Cool the tubes for 1-2 min before using for PCR or store at -20◦C for later 
use. 
b. PCR and PCR gel formation, loading and visualization: 
  The below procedure is a general procedure and all reagents, solution 
amounts, PCR reaction times and primers had to be customized depending on 
which gene was being genotyped.  The different primers used were: 
       hAPP forward primer :GCC GTT GAC AAG TAT CTC GAG ACA CCT GG 
       hAPP reverse primer: GTG TCT CCA CCA GCT GCT GTC TCT CGT TGG C 
       PS-1 forward primer: GAC AAC CAC CTG AGC AAT AC 
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       PS-1 reverse primer: CAT CTT GCT CCA CCA CCT GCC 
   The general PCR procedure is as a follows: 
a) To an autoclaved microcentrifuge tube add the reagents below in the 
amounts specified for 16 PCR samples: 
  40 µl  Hot start 10X Reaction buffer 
  24 µl  25 mM MgCl2 
  3.2 µl  Forward primer (20 µM) 
  3.2 µl  Reverse primer (20 µM) 
  8 µl  10 mM dNTP mix 
  301.6 µl ddH2O 
  4 µl  Hot start Taq DNA polymerase 
(All above reagents, with the exception of the primers and dNTP (both are from 
Invitrogen) are from Fermentas Inc. and are stored at -20◦C) 
b) Aliquot out 24 µl of the above master mix to autoclaved PCR tubes. 
c) Add to each tube 1 µl of digested tissue sample. 
d) Vortex and briefly tap the tube so all solution is at the bottom. 
e) Place the samples in a thermal cycler and set the machine to the parameters 
below: 
 For PS-1 genotyping with Hot start Taq: 
 First stage:  1 cycle at 95◦C for 4 min 
 Second stage:   35 cycles of: 1) Denature step: 94◦C for 30 sec 
                                                                2) Anneal step: 52◦C for 30 sec 
                                                                3) Extension step: 72◦C for 1 min 
 Third stage:    1cylcle of 72◦C for 10 min    
 For APP genotyping with Hot start Taq: 
 First stage:  1 cycle at 95◦C for 4 min. 
 Second stage:   28 cycles of: 1) Denature step: 94◦C for 1 min 
                                                                2) Anneal step: 55◦C for 1 min 
                                                                3) Extension step: 72◦C for 2 min 35 sec 
f) Pour a 1% agarose gel (1 g ultra pure agarose, Invitrogen; 100 ml 0.5X TBE; 
5 µl ethidium bromide, Sigma-Aldrich) into the proper PCR gel apparatus.  
NB: 0.5X TBE is from a 1X TBE stock (10.8 g Tris Base, J.T. Baker; 5.5 g 
boric acid, EM Science Inc; 4 ml 0.5 M EDTA, pH 8.0, EMD Chemicals Inc; 
1000 ml ddH2O). 
g) Wait at least 30 min for the gel to solidify and then add 0.5X TBE buffer. 
h) Load 2.5 µl of protein ladder (Fermentas Inc) into the first well. 
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i) In each of the next wells load 2 µl of 6XLB (30% glycerol in water, MP 
Biomedicals; 0.25% bromophenol blue, Sigma-Aldrich; 0.25% xylene 
cyanol FF, Sigma-Aldrich) and 10 µl of the PCR sample. 
j) Set apparatus to a constant voltage of 100 V and run for the suitable amount 
of time (approximately 20-30 min for PS-1 and APP, respectively). 
k) Visualize the PCR bands under UV light. 
 
2.2.11 HPLC 
 Six month old mice (The Jackson Laboratory) were euthanized by injection 
of sodium pentobarbital and the cortex, cerebellum and hippocampus were removed 
and stored at -70◦C.  A sample section from these brain regions were then measured 
for specific biogenic amines through HPLC with electrochemical detection.  This 
measurement was carried out in collaboration with Dr. Glen Baker at the University 
of Alberta and the exact method is explained in Baker et al (129).   
 
2.2.12 Water maze 
 For two straight days, 6 month old mice (The Jackson Laboratory) were 
subjected to a water maze test.  This is a behavioural test which measures short-term 
memory by allowing the mouse to recognize and remember visual markers placed on 
the walls of the pool.  On the first day, each mouse is placed, at a designated 
direction, into a pool of water at 22◦C for 1 min or until they find the hidden 
platform in the northwest quadrant.  This is done for a total of 20 randomly ordered 
directions.  On the second day the platform is removed and each mouse is placed in 
the pool only at the South direction and the swimming pattern is recorded for 1 min.  
Analysis of the swimming pattern was done through the EthoVision program from 
Noldus Information Technology Inc (Leesburg, VA, USA).  
   
2.2.13 Statistical analysis 
 Data were analyzed by unpaired Students t-test (two groups) or analysis of 
variance (ANOVA) (more than two groups) with significance set at P<0.05.  Post-
hoc analysis relied on the Bonferroni multiple comparisons’ test (GraphPad 
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Software, Inc., San Diego, CA, USA). Data are shown as mean ± standard error of 
the mean.  
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3 RESULTS 
 
 
3.1 PS-1 is expressed in the mitochondrial fraction 
  
 The major objective of this work is to examine the possible functional 
interaction between PS-1 and MAO.  As such, the distribution of PS-1 in the cell had 
to be examined to determine if it might be expressed in the mitochondria, where 
MAO is located and functions.  It is well established that PS-1 exists in the 
membranes of the ER and golgi body but several groups have shown, through 
immunoelectron microscopy, that PS-1 and other components of the γ-secretase 
complex are also found in the mitochondrial membrane (13, 14).  Subcellular 
fractionation of HT-22 and HEK 293A cells, followed by Western Blot analysis 
confirms that PS-1 can be found in the mitochondrial-enriched fraction of both cell 
lines (Figure 3.1). 
 
 
3.2 Chromatogram sequences of PS-1 WT, D257A, Y115H, ΔEx9 
and M146V  
  
 The PS-1 plasmid constructs obtained from Dr. G. Levesque were sequenced 
and confirmed against NCBI GenBank sequences.  The complete PS-1 WT construct 
was sequenced with the T7, D257AF2 and PS1END primers (Figure 3.2a - Figure 
3.2c).  The PS-1 M146V construct was created by mutating the PS-1 wild-type DNA 
with Stratagene’s QuikChange® Site-Directed Mutagenesis Kit (see section 2.2.3 for 
the exact protocol). 
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Figure 3.1: Western blot analysis of the subcellular distribution of PS-1.  
Subcellular fractionation was performed on HT-22 and HEK 293A cells and then 
each fraction (TCL: total cell lysate, P1: nuclear/ER/cell debris, P2: mitochondria-
enriched, S: soluble/cytosol) was resolved by SDS-PAGE, transferred to membrane 
and probed with the primary antibody PS-1.  There is a detectable amount of PS-1 in 
the mitochondrial fraction of both HT-22 and HEK 293A cells. (n=1)  
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Figure 3.2a: Chromatogram of PS-1 wild-type (WT) nucleotides 1-590. 
Nucleotide 1 of the PS-1 cDNA sequence is at position 231 of the chromatogram, 
with the “ATG” start codon boxed in green). The wildtype codons (underlined in 
purple) and the corresponding amino acid, and the mutated codon (underlined in 
yellow) and corresponding amino acid substitution are shown. 
56 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2b: Chromatogram of PS-1 wild-type (WT) nucleotides 590-1110. 
Nucleotide 590 of the PS-1 cDNA sequence is at position 301 of the chromatogram 
and nucleotide 1110 is at position 821 of the chromatogram.  The wildtype codons 
(underlined in purple) and the corresponding amino acid, and the mutated codon 
(underlined in yellow) and corresponding amino acid substitution are shown (the 
Exon 9 amino acids, underlined in purple, are deleted in the PS-1 ΔEx9 mutant). 
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Figure 3.2c: Chromatogram of PS-1 wild-type (WT) nucleotides 1110-1400. 
Nucleotide 1110 of the PS-1 cDNA sequence is at position 191 of the chromatogram 
and nucleotide 1400 is at position 481 of the chromatogram.  The “TAG” stop codon 
is boxed in red.    
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3.3 PS-1 mutant proteins affect basal and Ca2+-sensitive MAO-A 
activity 
 
 Wildtype (WT) and mutant (PS-1 D257A, Y115H, ΔEx9 and M146V) PS-1 
proteins were overexpressed in HT-22 cells for 24 hours (Figure 3.3).  The 
corresponding homogenates were incubated in the absence or presence of 1 mM 
Ca2+ and assayed for MAO enzymatic activity.  Endogenous MAO-A activity is 
altered differently by the five PS-1 constructs (Figure 3.4).  Overexpression of the 
PS-1 ΔEx9 protein induced basal MAO-A activity compared to control cells.  The 
PS-1 Y115H increased Ca2+-sensitive MAO-A activity and the ΔEx9 protein showed 
a tendency to increase Ca2+-sensitive MAO-A activity compared to their basal 
activity levels.  The PS-1 M146V protein did not alter MAO-A activity compared to 
vector control.  The PS-1 WT and dominant negative D257A proteins decreased the 
Ca2+-sensitive MAO-A activity, but did not alter basal MAO-A activity. 
 The effect of overexpression of PS-1 proteins on endogenous MAO-B 
activity is not altered as much with the five PS-1 constructs (Figure 3.5).  Although 
tendencies (i.e. increased with PS-1 ΔEx9 and decreased with PS-1 Y115H and 
M146V) were observed, these were not statistically significant.  
 
 
3.4 PS-1 proteins differentially affect intracellular free Ca2+ levels in 
PS-1 transfected HT-22 cells  
  
 Because some effects of PS-1 on endogenous MAO-A activity seemed to 
implicate Ca2+, the effect of PS-1 constructs on intracellular free Ca2+ levels was 
examined.  Confocal laser fluorescent microscopy was used to examine Fluo-3AM 
fluorescence (once inside the cell this compound binds free Ca2+ and fluoresces 
green).  With low magnification there was generally no increase in cytoplasmic Ca2+ 
levels in cells expressing the PS-1 constructs compared to wild-type or control 
(empty vector), although there was an unexpected decrease in Fluo-3AM   
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Figure 3.3: Western blot of over-expressed PS-1 constructs.  Five PS-1 
constructs and the pcDNA3.1 vector were transfected into HT-22 cells for 24 hours 
and the 20 kDa species of PS-1 was detected by Western blot (the low level of 
detection in the ΔEx9 sample confirms the absence of  Exon 9).  
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Figure 3.4: Activity assay graph of MAO-A with and without Ca2+ in PS-1 
transfected HT-22 cells.  Endogenous MAO-A activity was measured in HT-22 
cells transfected with either the pcDNA3.1 empty vector (control), PS-1 WT, D257A, 
Y115H, ΔEx9 or M146V constructs (black solid bars) (one-way ANOVA and 
Bonferroni’s post hoc test were used; P<0.05; n=3).  Endogenous MAO-A activity 
was also measured in the same HT-22 transfected cells but treated with 1 mM Ca2+ 
for 20 min during the assay (horizontal lined bars) (Unpaired t tests were used; two-
tailed P<0.05; n=3).  Significant increases in basal MAO-A activity were found in 
ΔEx9 expressing cells. MAO-A activity was also enhanced by Ca2+ in vector 
transfected control (CTL) and Y115H samples. 
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Figure 3.5: Activity assay graph of MAO-B with and without Ca2+ in PS-1 
transfected HT-22 cells.  Endogenous MAO-B activity was measured in HT-22 
cells transfected with either the pcDNA3.1 empty vector (control), PS-1 WT, D257A, 
Y115H, ΔEx9 or M146V  constructs (black solid bars) (one-way ANOVA and 
Bonferroni’s post hoc test were used; P<0.05; n=3).  Endogenous MAO-B activity 
was also measured in the same HT-22 transfected cells but treated with 1 mM Ca2+ 
for 20 min during the assay (horizontal lined bars) (Unpaired t tests were used; two-
tailed P<0.05; n=3).  Only cells expressing the control vector and treated with Ca2+ 
have a significant increase in MAO-B activity compared to basal MAO-B level.  
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fluorescence in cells expressing the PS-1 ΔEx9 protein (Figure 3.6).  Using higher 
magnification I found that cells expressing the PS-1 Y115H mutant seemed to have 
more Ca2+ concentrated around the nuclear membrane than the other cells and that 
the dominant negative catalytically inactive PS-1 D257A mutant resulted in a diffuse 
Ca2+ signal- including throughout the nucleus (Figure 3.7).  The reasons behind 
these effects are unclear, but appear to indicate that the effects of PS-1 proteins on 
MAO-A activity are not restricted to their ability to affect Ca2+ availability.   
 
 
3.5 Overexpression of Calbindin D-28K diminishes the effect of PS-1 
proteins on MAO-A activity in HT-22 cells 
  
 Basal and Ca2+-sensitive MAO-A activity (only MAO-A was measured 
because of the lack of Ca2+-related PS-1 effects seen with MAO-B activities) was 
determined in HT-22 co-expressing the Ca2+-binding protein Calbindin D-28K (CB-
28K) and the PS-1 proteins (WT, Y115H, ΔEx9 and M146V).  The over-expression 
of CB-28K, compared to its empty vector pREP, is not as clear as expected; this has 
been found to be a limitation of the antibody used (Figure 3.8).  Figure 3.9 shows 
that co-expression of CB-28K clearly blocks the Ca2+-sensitive MAO-A activity in 
control cultures.  Its effect on the other cultures is not clear as the individual 
standard deviations are so large, rendering effects inconclusive. 
 
 
3.6 Treatment of HT-22 cells expressing PS-1 Y115H proteins with 
MAO inhibitors decrease reactive oxygen species formation 
 
 Given that PS-1-mediated increases in MAO-A activity were observed, 
proportional increases in peroxy radical production by the cell is expected. The 
effect of  PS-1 on  the  production  of peroxy radical  species was  examined by DCF  
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   a)    Empty Vector    b)        Wildtype  c)          D257A 
 
 
 
 
 
 
   d)        Y115H    e)        ΔEx9   f)          M146V 
 
 
 
 
 
 
 
Figure 3.6: Fluo-3AM detection of intracellular free Ca2+ in PS-1 transfected 
HT-22 cells (20X magnification).  The empty vector, pcDNA3.1, and five PS-1 
proteins, PS-1 WT, D257A, Y115, ΔEx9 and M146V were over-expressed in HT-22 
cells for 24 hours.  Fluo-3AM was added to the cells and the level of fluorescence 
(directly correlated to free Ca2+) was observed under 20X magnification using 
confocal laser fluorescence microscopy.  Only ΔEx9 (e) had an obvious decrease in 
cytosolic Ca2+ levels.  All other mutated PS-1 constructs (c,d,f) had an increase over 
WT (b) but not over vector treated cells (a). (n=4) 
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Figure 3.7: Fluo-3AM detection of intracellular free Ca2+ in PS-1 transfected 
HT-22 cells (40X magnification).  The empty vector, pcDNA3.1, and five PS-1 
proteins, PS-1 WT, D257A, Y115, ΔEx9 and M146V and were over-expressed in 
HT-22 cells for 24 hours.  Fluo-3AM was added to the cells and the level of 
fluorescence was observed under 40X magnification by a confocal laser fluorescent 
microscope.  Only cells expressing PS-1 Y115H and D257A seemed to affect Ca2+ 
localization in the cell. PS-1 Y115H (d) seemed to have more Ca2+ concentrated 
around the nuclear membrane and PS-1 D257A (c) resulted in a diffuse Ca2+ signal 
including throughout the nucleus. (n=4) 
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Figure 3.8: Western blot of co-transfected CB-28K and PS-1 constructs.  The 
two vectors, pcDNA3.1 and pREP, and five PS-1 constructs and were transfected 
into HT-22 cells for 24 hours.  The PS-1 constructs were detected with the primary 
antibody PS-1.  At the same time CB-28K was co-transfected in each cell culture 
dish containing PS-1 WT, the four mutated PS-1 constructs or CB-28K only.  The 
over-expressed CB-28K was detected with the primary antibody Calbindin D28K.  
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Figure 3.9: Activity assay graph of MAO-A with and without Ca2+ in PS-1 and 
CB-28K co-transfected HT-22 cells.  Endogenous MAO-A activity was measured 
in HT-22 cells transfected with either the pcDNA3.1 and pREP empty vectors 
(control), PS-1 WT, D257A, Y115H, ΔEx9, M146V or CB-28K constructs (black 
solid bars) (n=3).  Endogenous MAO-A activity was also measured in the same HT-
22 transfected cells but treated with 1 mM Ca2+ for 20 min during the assay 
(horizontal lined bars) (n=3).  Basal MAO-A activity in familial PS-1 constructs are 
the same as before but co-transfection of CB-28K in CTL and especially Y115H 
expressing cells reduce MAO-A activity in the presence of Ca2+. 
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fluorescence using a laser-scanning confocal fluorescence microscope.  PS-1 WT-
and ΔEx9-expressing HT-22 cells had less fluorescence than the vector control PS-1 
Y115H-expressing cells (Figure 3.10).  The effects of clorgyline (MAO-A inhibitor) 
and deprenyl (MAO-B inhibitor) were marginal in all groups except in cells 
expressing PS-1 Y115H where both inhibitors prevented peroxy radical production.  
 
 
3.7 PCR results of wild-type and transgenic PS-1(M146V) mice 
  
 To determine if the effects of PS-1 proteins were relevant in vivo, wild-type 
and PS-1 transgenic mice brains (these mice over-express the PS-1 (M146V) protein) 
were collected and used to assay both basal and Ca2+-sensitive MAO activities.  All 
mice were genotyped (section 2.2.10) to confirm the presence of the transgene. For 
purposes of comparison, this portion of the study included mice that were transgenic 
for the human APP (hAPP) gene carrying the KM670/671NL Swedish familial AD-
related mutation.  
 Figure 3.11 depicts genotyping results (PCR) and reveals that mice assigned 
numbers 38, 39, 57, 58, 59, 70, 73, 80, 87, 89, 92, 93, 94, 98 were PS-1 positive and 
the mice assigned numbers 31, 37, 52, 54, 55, 56, 83, 90, 91, 95, 96, 97 were PS-1 
negative (wildtype, control).  Figure 3.12 depicts genotyping results and reveals that 
mice numbered with 37, 59, 60, 73, 77, 88, 93, 94, 97 were hAPP positive and the 
mice numbered with 31, 38, 39, 52, 55, 57, 58, 70, 83, 87, 89, 90, 91, 92, 95, 96, 98 
were APP negative (wildtype, control). 
 
 
3.8 Transgenic PS-1 mice brains and endogenous MAO-A activity 
  
3.8.1 Transgenic PS-1(M146V) cortical MAO-A activity is sensitive to Ca2+ 
 Cortical tissue from WT and transgenic PS-1 (M146V) mice were 
homogenized in potassium phosphate buffer, and basal and Ca2+-sensitive MAO 
activity was determined.  In WT mouse cortical homogenates MAO-A activity did  
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Figure 3.10a: DCF detection of reactive oxygen species in PS-1 transfected HT-
22 cells treated with vehicle, clorgyline or deprenyl (continued on the next three 
pages).  Vector and PS-1 proteins, WT, Y115H and ΔEx9, were over-expressed in 
HT-22 cells for 24 hours and treated with vehicle, clorgyline or deprenyl 4 hours 
post-transfection.  DCF was added to the cells and the level of fluorescence was 
monitored under 10X magnification by a confocal laser fluorescence microscope.  
Vehicle-treated PS-1 WT and ΔEx9-expressing cells had less fluorescence than 
vector-transfected and PS-1 Y115-expressing cells.  Clorgyline and deprenyl 
treatment had little effect in most cultures, but clearly inhibited DCF fluorescence in 
cells expressing PS-1 Y115H. (n=3; two trials are shown in each picture and all left 
or right sides correspond to one trial) 
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Figure 3.10b: DCF detection of reactive oxygen species in PS-1 transfected HT-
22 cells treated with vehicle, clorgyline or deprenyl.  (These pictures depict the 
DCF fluorescence in PS-1 WT-expressing HT-22 cells. This is a continuation of the 
data presented on page 69.) 
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Figure 3.10c: DCF detection of reactive oxygen species in PS-1 transfected HT-
22 cells treated with vehicle, clorgyline or deprenyl. (These pictures depict the 
DCF fluorescence in PS-1 ΔEx9-expressing HT-22 cells. This is a continuation of 
the data presented on page 69). 
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Figure 3.10d: DCF detection of reactive oxygen species in PS-1 transfected HT-
22 cells treated with vehicle, clorgyline or deprenyl. (These pictures depict the 
DCF fluorescence in PS-1 Y115H-expressing HT-22 cells. This is a continuation of 
the data presented on page 69). 
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      e)                                                          f) 
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Figure 3.11: PCR results of PS-1 positive mice. The brain tissues of 26 mice were 
first digested and then PCR was carried out.  The mice designated numbers 38, 39, 
57, 58, 59, 70, 73, 80, 87, 89, 92, 93, 94, 98 are shown to have a PS-1 positive PCR 
band comparable to the positive control lane (P) and the mice designated 31, 37, 52, 
54, 55, 56, 83, 90, 91, 95, 96, 97 are shown to have no PCR band as in the negative 
control lane (N). 
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Figure 3.12: PCR results of APP positive mice. The brain tissues of 26 mice were 
first digested and then PCR was carried out.  The mice designated numbers 37, 59, 
60, 73, 77, 88, 93, 94, 97 are shown to have a APP positive PCR band comparable to 
the positive control lane (P) and the mice designated 31, 38, 39, 52, 55, 57, 58, 70, 
83, 87, 89, 90, 91, 92, 95, 96, 98 are shown to have no PCR band as in the negative 
control lane (N). 
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not respond to incubation with increasing concentrations of Ca2+ (Figure 3.13a).  In 
contrast, in transgenic mouse cortical homogenates, there is a tendency for MAO-A 
activity levels to increase with increasing concentrations of Ca2+ (Figure 3.13b).   
 
3.8.2 Transgenic PS-1(M146V) cerebellar MAO-A activity is not sensitive to 
Ca2+ 
 Cerebellar homogenates from WT and transgenic PS-1 (M146V) mice were 
also examined for MAO-A activity. Neither WT (Figure 3.14a) nor PS-1(M146V) 
(Figure 3.14b) cerebellar MAO-A activities responded significantly to Ca2+. 
 
 
3.9 Transgenic PS-1 mice brains and endogenous MAO-B activity 
  
3.9.1 Transgenic PS-1(M146V) cortical MAO-B activity is sensitive to Ca2+ 
 MAO-B activity in cortical tissue from WT and transgenic PS-1 (M146V) 
mice were also examined, for purposes of comparison. Figure 3.15 reveals that 
cortical MAO-B activity in WT mice does not respond to incubation with increasing 
concentrations of Ca2+, but that cortical MAO-B activity in transgenic PS-1(M146V) 
mice does respond, although significance is not reached. 
 
3.9.2 Cerebellar MAO-B from transgenic PS-1 mice is not sensitive to Ca2+ 
 Cerebellar homogenates from WT and transgenic PS-1 (M146V) mice were 
also examined for MAO-B activity. Neither WT (Figure 3.16a) nor PS-1(M146V) 
((Figure 3.16b) cerebellar MAO-B activities responded to incubation with Ca2+. 
 
 
3.10 Biogenic amine levels in the Cortex, Cerebellum and 
Hippocampus of WT and PS-1 transgenic mice 
 
 As the expression of the PS-1(M146V) transgene appears to affect both 
MAO-A and MAO-B activities in a region-specific manner, regional levels of  
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Figure 3.13: MAO-A and Ca2+ concentration-response curves from cortical 
homogenates of WT and PS-1 mice. a) WT mice. Increasing concentrations of 
Ca2+ slightly increase WT MAO-A activity compared to their basal level (0mM 
Ca2+). b) Transgenic PS-1(M146V) mice.  The basal level of PS-1 MAO-A activity 
(0 mM) compared to the basal level of WT mice (100%) is moderately increased.  
Increasing concentrations of Ca2+ greatly increase PS-1 mice MAO-A activity 
compared to their basal level (0 mM) (*: one-way ANOVA and Bonferroni’s post 
hoc test was used to compare PS-1 or WT activity with different concentrations of 
calcium, P<0.05; #: unpaired t tests was used to compare activity between PS-1 and 
WT at each concentration, one-tailed, P<0.05; n=3) 
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Figure 3.14: MAO-A and Ca2+ concentration-response curves from cerebellar 
homogenates of WT and PS-1 mice. a) WT mice. Increasing concentrations of 
Ca2+ slightly increase WT MAO-A activity compared to their basal level (0 mM 
Ca2+). b) Transgenic PS-1(M146V) mice.  The basal level of PS-1 MAO-A activity 
(0 mM) compared to the basal level of WT mice (100%) is greatly increased.  
Increasing concentrations of Ca2+ produce a tendency for moderate increases in PS-1 
mice MAO-A activity compared to their basal level (0 mM). (n=3). 
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Figure 3.15: MAO-B and Ca2+ concentration-response curves from cortical 
homogenates of WT and PS-1 mice. a) WT mice. Increasing concentrations of 
Ca2+ do not increase WT MAO-B activity compared to their basal level (0 mM Ca2+). 
b) Transgenic PS-1(M146V) mice.  The basal level of PS-1 MAO-B activity (0 mM) 
compared to the basal level of WT mice (100%) is increased and in the presence of 
increasing concentrations of Ca2+ PS-1 mice increase- in an apparent biphasic 
manner- MAO-B activity compared to their basal level (0 mM). (n=3). 
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Figure 3.16: MAO-B and Ca2+ concentration-response curves from cerebellar 
homogenates of WT and PS-1 mice. a) WT mice. Increasing concentrations of 
Ca2+ do not increase WT MAO-B activity compared to their basal level (0 mM Ca2+). 
b) Transgenic PS-1(M146V) mice.  The basal level of PS-1 MAO-B activity (0 mM) 
compared to the basal level of WT mice (100%) is somewhat increased and in the 
presence of increasing concentrations of Ca2+, PS-1 mice do not increase MAO-B 
activity compared to their basal level (0 mM). (n=3). 
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biogenic amine substrates for MAO-A and MAO-B, e.g. 5-HT, dopamine (DA) and 
noradrenaline (NA) were analyzed (this was in collaboration with Dr. G.B. Baker, 
University of Alberta).  
  In the cortex of PS-1 mice it was found that there is a significant decrease in 
DOPAC compared to WT, which possibly shows that more DA is being metabolized 
to HVA (Figure 3.17a).  There was also an unusual decrease in 5-HT’s metabolite 5-
HIAA.   
In contrast, for the cerebellar region, there was a significantly reduced 
amount of DA, NA and 5-HT levels, compared to WT.  Along with the decreased 
DA there was a tendency for an increase in its metabolite HVA.  Unfortunately I 
could not verify if the decreased NA was a result of it being metabolized because 
NA’s metabolites were not quantified (Figure 3.17b). 
 Although the hippocampal MAO activity could not be measured because of 
inadequate tissue amounts required for the MAO activity assay, I still decided to 
examine if any changes in the cortex and cerebellum could be found in the 
hippocampus.  Interestingly in PS-1 mice, I found a significantly larger amount of 
DA compared to WT mice and thus a tendency for more HVA metabolites was 
observed but this metabolite increase was not statistically significant probably due to 
the large standard deviation (Figure 3.17c).  All other amines measured had similar 
amounts between WT and PS-1 mice. 
 
 
3.11 Endogenous MAO protein levels in the Cortex, Cerebellum and 
Hippocampus of WT and PS-1 transgenic mice 
 
 Since the MAO activity was found to be different between WT and 
transgenic mice and between the cortex and cerebellum, I tested to see if this 
difference was due to differences in MAO protein levels.  Furthermore, because the 
difference in MAO activity seen between regions of transgenic PS-1 mice brains was 
in the presence of Ca2+, I tested if some well-known and not so well-known 
endogenous molecules regulating Ca2+ availability were altered.  
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Figure 3.17a: Biogenic amine concentrations from cortical homogenates of WT 
and PS-1 mice.  HPLC was performed on cortical homogenates of WT (black solid 
bars) and PS-1 (horizontal lined bars) mice and specific biogenic amine levels were 
measured.  DOPAC and 5-HIAA levels were significantly decreased in PS-
1(M146V) mice (One-tailed t-tests; *: P<0.05; n=6). 
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Figure 3.17b: Biogenic amine concentrations from cerebellar homogenates of 
WT and PS-1 mice.  HPLC was performed on cerebellar homogenates of WT 
(black solid bars) and PS-1 (horizontal lined bars) mice and specific biogenic amine 
levels were measured.  A significantly reduced level of DA, NA and 5-HT were 
found (One-tailed t-tests: *: P<0.05, **: P<0.01; n=6). 
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Figure 3.17c: Biogenic amine concentrations from hippocampal homogenates of 
WT and PS-1 mice.  HPLC was performed on hippocampal homogenates of WT 
(black solid bars) and PS-1 (horizontal lined bars) mice and specific biogenic amine 
levels were measured.  In comparison to WT, an increased level of the DA was 
found (One-tailed t-tests; **: P<0.01; n=5). 
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3.11.1 Endogenous MAO protein levels in the cortex 
 Genotyped cortex tissue from 6month old WT and transgenic PS-1 (M146V), 
APP (Swe) or PS-1/APP double transgenic mice were homogenized and a Western 
blot was carried out as outlined in section 2.2.7.  Then the primary antibodies anti-
MAO-A (H-70), anti-MAO-B (C-17), anti-CB-28K and anti-phospho-p38 (MAP 
kinase) were applied.  Figure 3.18 unexpectedly shows that the full length MAO-A 
protein in double transgenic PS-1/APP mice is completely lost in the cortex, and 
between WT and PS-1 mice the MAO-A protein levels are exactly the same.  
Therefore the increased response of basal MAO-A in the cortex region of PS-1 mice 
compared to WT (Figure 3.13) is not due to increased protein levels of MAO-A.  
Concerning MAO-B, there are no changes observed in protein levels between WT 
and PS-1 mice.  It is likely then that the higher basal MAO-B activity in PS-1 mice 
is not due to higher MAO-B protein levels since there is no drastic increase in 
MAO-B.  For the other proteins, calbindin (a known inhibitor of Ca2+) and phospho-
p38 (recently found in our lab to bind and inhibit Ca2+ (data not shown)) they are, 
respectively, the same amount or not detected.  So the increased MAO-A and MAO-
B response to Ca2+ observed cannot be due to altered protein levels of either 
calbindin or activated p38. 
 
3.11.2 Endogenous MAO protein levels in the cerebellum 
 Genotyped cerebellum tissue from 6month old WT and transgenic PS-1 
(M146V), APP (Swe) or PS-1/APP double transgenic mice were then prepared and 
assayed in the same method as the cortex tissue in section 3.11.1.  Similar results 
were obtained in the cerebellum as was seen in the cortex region of all mice tested 
(Figure 3.19).  Specifically, it was found that in cerebellar tissue full-length MAO-A 
is lost in bigenic APP/PS-1 mice.  Also this time compared to WT, PS-1 mice have a 
slightly smaller amount of MAO-A protein but still this illustrates that the increased 
MAO-A activity in PS-1 mice, found in section 3.8.2, cannot be due to increased 
MAO-A protein levels.  MAO-B, once again, was observed to have no significant 
difference in protein levels between WT and PS-1 mice.  Lastly in all 
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Figure 3.18: Western blot of protein levels in the cortex of 6 month old WT and 
transgenic PS-1 (M146V), APP (Swe) or PS-1/APP mice.  MAO-A was detected 
with the primary antibody MAO-A (H-70), MAO-B was detected with the primary 
antibody MAO-B (C-17), CB-28K was detected with the primary antibody 
Calbindin D28k and activated p38 was detected with phospho-p38 MAP kinase 
antibody.  Full length MAO-A protein in double transgenic PS-1/APP mice is 
completely lost in the cortex, and between WT and PS-1 mice the MAO-A/B protein 
levels are exactly the same. (n=3) 
 
85 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19: Western blot of protein levels in the cerebellum of 6 month old WT 
and transgenic PS-1 (M146V), APP (Swe) or PS-1/APP mice.  MAO-A was 
detected with the primary antibody MAO-A (H-70), MAO-B was detected with the 
primary antibody MAO-B (C-17), CB-28K was detected with the primary antibody 
Calbindin D28k and activated p38 was detected with phospho-p38 MAP kinase 
antibody.  Full-length MAO-A is lost in bigenic APP/PS-1 mice and compared to 
WT, PS-1 mice have a slightly smaller amount of MAO-A protein. (n=3) 
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mice, calbindin protein levels are unchanged and there is no activated p38 (MAPK) 
detected. 
 
3.11.3 Endogenous MAO protein levels in the hippocampus 
 Next, I chose to look at one last region, the hippocampus, to see if the same 
protein amounts were also seen there.  Once again, I took genotyped hippocampal 
tissue from 6month old WT and transgenic PS-1 (M146V), APP (Swe) or PS-1/APP 
double transgenic mice and prepared and assayed the tissue in the same method as 
described in the past two sections.  Concerning MAO-B, CB-28K and activated p38, 
identical results were obtained in the hippocampus as was seen in the cortex and 
cerebellum regions of all mice tested but there are some differences in MAO-A 
protein levels (Figure 3.20).  In the hippocampus of the double PS-1/APP transgenic 
mice there is only a decrease, not a complete loss, of MAO-A full length protein.  
Also in PS-1 mice there is a slightly smaller amount of full-length MAO-A 
compared to WT and a large smear of smaller bands appear around and below 
49kDa.   
 Taken together, the activity graphs and immunoblots from the 3 brain regions 
show that there is an obvious modulation of MAO-A activity in the cortex and 
cerebellum and/or full-length protein levels all in regions by PS-1 but with respect to 
MAO-B, there is one PS-1 related change in activity in the cortex, no activity change 
in the cerebellum and all protein levels seem to be unchanged too.  Combining these 
results with the lack of changes in MAO-B activity in the cell culture studies 
described previously, I then chose to focus more on characterizing specifically the 
PS-1 and MAO-A interaction.    
  
3.11.4 MAO activity and biogenic amine levels in bigenic PS-1/APP mice 
 Preliminary data from the cortical homogenates of PS-1/APP mice show that 
these mice still have MAO-A and -B activity (Figure 3.21), even though there was 
little or no observable full-length MAO-A in these mice, but no noticeable changes 
in biogenic amine levels because of the large standard deviations (Figure 3.22). 
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Figure 3.20: Western blot of protein levels in the hippocampus of 6 month old 
WT and transgenic PS-1 (M146V), APP (Swe) or PS-1/APP mice.  MAO-A was 
detected with the primary antibody MAO-A (H-70), MAO-B was detected with the 
primary antibody MAO-B (C-17), CB-28K was detected with the primary antibody 
Calbindin D28k and activated p38 was detected with phospho-p38 MAP kinase 
antibody.  In bigenic APP/PS-1 mice, only a decrease, not a complete loss, of MAO-
A full length protein occurs.  In PS-1 mice, there is a slightly smaller amount of full-
length MAO-A compared to WT and a large smear of smaller bands appear around 
and below 49kDa. (n=3) 
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Figure 3.21: MAO and Ca2+ concentration-response curves from the cortex of 
bigenic PS-1/APP mice. a) MAO-A activity. Increasing concentrations of Ca2+ 
greatly increase MAO-A activity compared to their basal level (0 mM Ca2+). b) 
MAO-B activity.  Increasing concentrations of calcium also increase MAO-B 
activity compared to their basal level (0 mM), but to a lesser extent than MAO-A. 
(n=1). 
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Figure 3.22: Biogenic amine concentrations from cortical homogenates of 
bigenic PS-1/APP mice.  HPLC was performed on cortical homogenates of WT 
(black solid bars) and bigenic PS-1/APP (horizontal lined bars) mice and specific 
biogenic amine levels were measured.  There was no obvious change in any biogenic 
amine (n=6). 
 
 
 
 
3.12 Co-transfection of PS-1 and MAO-A DNA results in the 
disappearance of full length MAO-A protein 
 
 So far, from my results, I have found that both PS-1 and Ca2+ are somehow 
altering MAO-A protein and activity.  Additionally, my results show that only some 
of the PS-1 constructs affect MAO-A by altering Ca2+ levels therefore the interaction 
between PS-1 and MAO-A may not always be indirect but sometimes direct.  To 
examine this hypothesis I first looked at three different cell lines, which are the HT-
22, PC12 and HEK 293A cell lines (more information about these cell lines can be 
found in section 2.1.4).  Previously we had only observed endogenous MAO so 
over-expressed PS-1 and MAO should have a more pronounced effect.  Thus, in 
each cell line I co-transfected one of the five PS-1 constructs and the MAO-A 
construct.  The empty vector controls, pcDNA3.1 and pCMV/myc/mito, were also 
transfected in each cell line.  All cells were transfected for 24 hours and the detailed 
procedure can be found in section 2.2.5.  After a Western blot was carried out 
(outlined in section 2.2.7) and the primary antibodies anti-MAO-A (H-70 and T-19) 
and anti-PS-1 (MAB5232) were used to measure any changes in protein amounts.  
 In both the HT-22 (Figure 3.23) and HEK 293A (Figure 3.24) cells there is, 
for the most part, the same effect.  Compared to HT-22 and HEK 293A cells co-
transfected with PS-1 WT, the cells expressing PS-1 D257A have a decreased 
amount of full length MAO-A protein and the cells expressing PS-1 Y115H have 
very little full length MAO-A protein.  In cells expressing the PS-1 ΔEx9 protein 
there is no change (HT-22 cells) or a very slight increase (HEK 293A) in full length 
MAO-A protein compared to cells expressing PS-1 WT.  Lastly, the cells expressing 
the PS-1 M146V protein seemed to have an increase in MAO-A full length protein.  
Surprisingly, in HEK 293A cells the N-terminal MAO-A antibody (T-19) seems to 
detect an N-terminal fragment around 40 kDa in HEK cells expressing the PS-1 
Y115H protein.  PC12 cells on the other hand, seem to have the same MAO-A 
protein amount in cells expressing the PS-1 D257A and ΔEx9 proteins compared to 
PS-1 WT (Figure 3.25).  Also in these cells the PS-1 Y115H construct decreased the 
full length MAO-A protein less than what was seen in the cell lines HT-22  
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Figure 3.23: Western blot of 24 hour co-transfection of PS-1 and MAO-A cDNA 
in HT-22 cells.  MAO-A was detected with the primary antibody MAO-A (H-70) 
and the primary antibody MAO-A (T-19).  PS-1 was detected with the primary 
antibody PS-1.  Cells expressing PS-1 D257A have a decreased amount of full 
length MAO-A protein and the cells expressing PS-1 Y115H have very little full 
length MAO-A protein, while cells expressing the PS-1 M146V protein seemed to 
have an increase in MAO-A full length protein. (n=1) 
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Figure 3.24: Western blot of 24 hour co-transfection of PS-1 and MAO-A DNA 
in HEK 293 cells.  MAO-A was detected with the primary antibody MAO-A (H-70) 
and the primary antibody MAO-A (T-19).  PS-1 was detected with the primary 
antibody PS-1.  Cells expressing PS-1 D257A have a decreased amount of full 
length MAO-A protein and the cells expressing PS-1 Y115H have very little full 
length MAO-A protein, while cells expressing the PS-1 ΔEx9 and M146V protein 
seemed to have an increase in MAO-A full length protein.  Also there seems to be an 
N-terminal fragment around 40 kDa in HEK cells expressing the PS-1 Y115H 
protein. (n=1) 
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Figure 3.25: Western blot of 24 hour co-transfection of PS-1 and MAO-A DNA 
in PC12 cells.  MAO-A was detected with the primary antibody MAO-A (H-70) and 
the primary antibody MAO-A (T-19).  PS-1 was detected with the primary antibody 
PS-1.  Cells expressing the PS-1 Y115H construct only decrease the full length 
MAO-A protein and the same increase in full length MAO-A protein, seen in HT-22 
and HEK 293 cells expressing the PS-1 M14V protein, is observed. (n=1) 
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and HEK 293A but the same increase in full length MAO-A protein, seen in HT-22 
and HEK 293A cells expressing the PS-1 M14V protein, is observed.   
 One conclusion from these data is that the PS-1 protein has a dual effect 
toward MAO-A in that it can indirectly affect MAO-A through its sensitivity to Ca2+ 
and directly affect MAO-A by reducing its full length form.   
 
 
3.13 Different PS-1 constructs and MAO physically interact to 
various extents 
 
 With possible MAO-A fragment proteins found in hippocampal tissue 
(Figure 3.20) and now in a cell line (Figure 3.24), it is highly likely that MAO, or at 
the very least, MAO-A is a novel substrate of PS-1.  If this is true, then the two 
proteins must be able to directly bind to each other in order for this cleavage to occur.  
The extent of this binding can be detected by immunoprecipitation.  All five PS-1 
DNA and the empty vector pcDNA3.1 were transfected into HT-22 cells for 24 
hours.  Then the PS-1 proteins were pulled down (immunoprecipitation protocol is 
in section 2.2.6) and MAO-A and MAO-B proteins were detected through Western 
blot (protocol is in section 2.2.7).  Figure 3.26 shows that PS-1 WT, Y115H, ΔEx9 
and M146V all interact with MAO-A to the same extent but PS-1 D257A interacts 
very little.  Concerning MAO-B, all of the PS-1 DNA interact with this isoform very 
little except for PS-1 Y115H.  This result is intriguing because in the previous 
section the PS-1 Y115H mutant was the only protein which could cause the 
complete loss of full length MAO-A protein.  So this stronger interaction between 
PS-1 Y115H and MAO, as found by this immunoprecipitation assay, could be one 
reason as to why this mutant can cause a loss of full-length MAO-A.  
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Figure 3.26: Western blot of Immunoprecipitation assay between PS-1 and 
MAO-A in HT-22 cells.  PS-1 proteins were expressed in HT-22 cells for 24 hours 
then PS-1 was pulled down, and MAO-A and MAO-B proteins were detected.  
MAO-A was detected with the primary antibody MAO-A (H-70) and MAO-B was 
detected with the primary antibody MAO-B (C-17).  PS-1 WT, Y115H, ΔEx9 and 
M146V all interact with MAO-A to the same degree and PS-1 D257A interacts very 
litttle.  All of the PS-1 proteins interacted very little with the B isoform except for 
PS-1 Y115H. (n=3) 
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3.14 DAPT, a γ-secretase inhibitor, can increase MAO-A activity 
 
3.14.1 DAPT-treated HT-22 cells overexpressing PS-1 have an increased MAO-
A activity 
 If PS-1 is mediating the loss of full length MAO-A protein (by a cleavage 
reaction), then MAO-A, as a novel substrate for PS-1/γ-secretase, must bind to the 
PS-1 substrate binding site and then be transferred to the catalytically active site to 
be cleaved.  To test this hypothesis I used DAPT, a chemical that is hypothesized to 
inhibit γ-secretase activity by preventing the passage of the substrate from PS-1’s 
binding site to its catalytic site. 
 Briefly, HT-22 cells were transfected with the pcDNA3.1 vector, PS-1 WT 
and M146V DNA for 24 hours according to the transfection protocol in section 2.2.5.  
After, the cells, radiolabelled serotonin substrate solution and DAPT solutions (with 
concentraton ranging from 100 nM-1 mM) were prepared and the MAO-A activity 
assay was carried out (procedure is in section 2.2.8).  The graph in Figure 3.27 
shows that the cells transfected with the pcDNA3.1 and PS-1 WT constructs have a 
similar MAO-A activity response to the increasing DAPT concentrations.  That is, 
they seem to peak at around 10 nM then decrease and peak again at 10 µM.  The 
cells expressing the PS-1 M146V protein have an increase in MAO-A activity with 
increases in the DAPT concentration and this increase peaks at around 1 µM.  At all 
concentrations though, except at 10 nM, the PS-1 M146V expressing cells have the 
higher MAO-A activity.     
 
3.14.2 DAPT-treated transgenic PS-1 mouse cortical homogenates have an 
increased MAO-A activity   
 We next took the cortex tissue of WT and transgenic PS-1 (M146V) 6 month 
old mice and tested the endogenous MAO-A activity after 20 min of DAPT 
treatment.  All of the tissue, radiolabelled serotonin substrate solution and DAPT 
solutions were prepared in a similar manner, as in section 3.14.1, and the MAO-A 
activity assay procedure was the same too.  
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 With the 6 month old cortical homogenates we found that the MAO-A 
activity decreases with increasing concentrations of DAPT in the WT mice, and the 
PS-1 cortical homogenates have the exact opposite effect (Figure 3.28).  As the 
DAPT concentrations increase, the MAO-A activity in the PS-1 mice tissue increase 
and peak at around 10 µM.  Therefore, in PS-1 transfected cells and now in PS-1 
transgenic mice tissue there is a consistent increase in MAO-A activity, with 
increasing concentrations of DAPT.  Because of the short treatment with DAPT, this 
increase cannot be due to protein synthesis or post-translational processing but is 
probably be due to a possible competitive interaction between these three molecules. 
 
 
3.15 PS-1 transgenic mice have a slightly inferior short term 
memory 
 
 To determine if PS-1 (M146V) transgenic mice had any deficits in short-term 
memory the Water maze test was carried out.  After one day of training, according to 
the method described in section 2.2.12, each mouse was placed in the pool only at 
the South direction and the swimming pattern was recorded for 1 min.  Figure 3.29 
illustrates that PS-1 mice do not perform as well as WT mice on the test day.  When 
frequency of entrance was measured, PS-1 mice (horizontal lined bars) enter the 
hidden platform area less than WT mice (black solid bars) mice, and spent a 
considerably larger time entering the corresponding platform area in the southeast 
quadrant.  When duration of time spent in each platform area was measured, PS-1 
mice (horizontal lined bars) swam mostly in the southeast and southwest quadrant 
platform areas while the WT mice (black solid bars) swam mostly in the northwest 
quadrant. 
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Figure 3.27: MAO-A and DAPT concentration-response curves from HT-22 
cells transfected with pcDNA3.1, PS-1 WT and M146V.  Endogenous MAO-A 
activity was measured in HT-22 cells transfected for 24 hours with either the 
pcDNA3.1 empty vector (control) (black solid bars), PS-1 WT (horizontal lined bars) 
or PS-1 M146V (diagonal lined bars) constructs, in the presence of DAPT (20 min 
treatment) (n=3).  Vector and WT expressing cells have a peak MAO-A activity 
around 10 nM then decrease and peak again at 10 µM.  PS-1 M146V expressing 
cells increase in MAO-A activity with increases in DAPT concentration and this 
increase peaks at around 1 µM. 
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Figure 3.28: MAO-A and DAPT concentration-response curves from PS-1 WT 
and M146V cortical tissue homogenates.  Endogenous MAO-A activity was 
measured in cortical homogenates from 6 month old WT (black solid bars) or PS-1 
(M146V) (horizontal lined bars) mice, in the presence of DAPT (20 min treatment).  
PS-1 cortical homogenates have a consistently higher, and sometimes significant 
increase, in MAO-A activity compared to WT cortical homogenates, with increasing 
concentrations of DAPT (Two-way ANOVA and Bonferroni’s post hoc test were 
used; P<0.05; n=3). 
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Figure 3.29: Behaviour data for WT and PS-1 (M146V) mice.  After one day of 
training each mouse was placed in the “South” part of the pool (water maze) and 
their swimming pattern was recorded for 1 min. a) PS-1 mice (horizontal lined bars) 
enter the hidden platform (HP) area (in NorthWest (NW) quadrant) marginally less 
than WT mice (black solid bars) mice, and spent a considerably larger time entering 
the corresponding platform area in the SouthEast (SE) quadrant.  b) PS-1 mice 
(horizontal lined bars) swam mostly in the SE and SW quadrants while the WT mice 
(black solid bars) swam mostly in the NW quadrant. (n=5) 
 
 
 
 
 
4 DISCUSSION 
 
 
4.1 Indirect effects of PS-1 
  
 Aside from cancer and cardiovascular disease, AD is one of the most 
prevalent disorders affecting the elderly (1, 2).  The human life span is increasing 
making this disease much more prominent and widespread than ever before, yet the 
exact mechanisms involved in AD-related pathology still remain unclear.  Looking 
at cellular models, including familial AD models, which reflect the more aggressive 
forms of AD (cf. sporadic AD), is of utmost importance to understanding how the 
disease progresses and to developing better treatments. Moreover because clinical 
symptoms in AD occur 20-30 years after neurodegeneration begins (3), prophylactic 
measures taken before or during the neurodegeneration phase may be a better 
approach than attempting to reverse an already existing AD pathology.  This study 
was undertaken to examine one of these neurodegenerative pathways in the brain.  
Based on the literature and previous work from our laboratory, a hypothesis 
suggesting a relation between PS-1, MAO and Ca2+ in AD was forwarded.   
  The expression of PS-1 in the mitochondrial-enriched fraction (which 
contains the majority of the cell’s MAO) was confirmed (13, 14).  Radioenzymatic 
MAO assays revealed that in comparison to WT PS-1, familial AD-related PS-1 
mutations (e.g. bearing Y115H, ΔEx9 and M146V mutations) cause an increase in 
basal and/or Ca2+-sensitive MAO-A activity in the hippocampal-derived HT-22 cells. 
These effects were most prominent in cells expressing the more aggressive PS-1 
Y115H and ΔEx9 mutants.  In contrast to MAO-A, only basal MAO-B activity in 
PS-1 ΔEx9-expressing cells was higher and there was no sensitivity to Ca2+ in cells 
expressing any of the three familial AD mutations.  This Ca2+ specificity for the 
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MAO-A isoform was also observed by Kosenko et al (110) in non-synaptic 
mitochondria of rat forebrain and in HT-22 cells by Cao et al  (111). Co-expression 
of the PS-1 proteins with CB-28K revealed mutant-specific effects on MAO-A 
activities.  For example, the vector- and PS-1 Y115H-expressing cells had their 
previous Ca2+-sensitive MAO-A response blocked, but this was less evident in PS-1 
ΔEx9-expressing cells.  The PS-1 M146V (100, 103, 124, 126) and PS-1 ΔEx9 (102, 
118) proteins are known to affect Ca2+ levels; perhaps the persistence of the effect of 
PS-1 ΔEx9 on MAO-A activity in the presence of CB-28K could be due to an 
increase in intracellular Ca2+ levels beyond the capacity of overexpressed CB-28K.  
Examination of free intracellular Ca2+, using the Ca2+-specific FLUO-3AM, revealed 
an unexpected decrease in Fluo-3AM fluorescence in cells expressing the PS-1 
ΔEx9 protein and no other obvious changes with the other PS-1 mutated proteins.  
Higher magnification revealed changes in the distribution of Ca2+ throughout the cell; 
for example, cells expressing the PS-1 Y115H protein seemed to have more Ca2+ 
concentrated around the nuclear membrane and cells expressing the PS-1 D257A 
protein had a diffuse Ca2+ signal- including throughout the nucleus.  The differences 
observed between the present and published data (wherein intracellular Ca2+ 
increases are associated with familial AD-related PS-1 proteins) could be attributed 
to the sensitivity of the reagent we used and/or because of our assay method, which 
did not allow for the proper quantitation of changes. If quantitative methods were 
used, subtle changes in HT-22 cell Ca2+ between the PS-1 constructs might be 
revealed.  Yet, Smith et al (104) have also observed that dissociated neurons in 
culture are not able to evoke increases in intracellular Ca2+ unless first depolarized.  
Thus, future experiments are required to confirm the effect of the familial AD-
related PS-1 constructs used herein on altering Ca2+ levels in HT-22 cells. 
 To determine if the cellular effects of PS-1 proteins could be even more 
apparent in constitutively expressing transgenic (Tg) animals, we used wild-type and 
PS-1 transgenic mice brains (these mice over-express the PS-1 M146V protein).  We 
chose to use 6 month-old mice as Aβ levels are non-existent at this time point (in 
fact, these PS-1 mice do not develop appreciable Aβ deposits even at 18 months of 
age (130)); all observed effects are then assumed to be APP/Aβ-independent. The 
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cortex, hippocampus and cerebellum represent three brain regions affected during 
AD.  Cortical homogenates from PS-1 mice had increased basal MAO-A and MAO-
B activities compared to age-matched WT littermates.  These results reflect the 
findings of Sparks et al (94) who used specific cortical areas from human AD brains.  
Moreover, in the presence of increasing concentrations of Ca2+ there was 
approximately a 25% increase in sensitivity of both MAO isoforms to Ca2+.  This 
increased MAO activity in the cortex would be expected to affect the levels of 
aminergic substrate of the enzyme (Figure 4.1 illustrates the MAO biogenic amine 
substrates that should be affected).  Indeed, levels of DA had a tendency to decrease 
in PS-1 cortices, but the levels of NA and 5-HT did not.  In PS-1 Tg mouse 
cerebellar extracts there was an increase in basal and Ca2+-sensitive MAO-A activity 
(approximately 12% increase), but MAO-B remained unaltered.  In corresponding 
homogenates there was a significant decrease in DA, NA and 5-HT and increases in 
the DA metabolite HVA.  The decreased 5-HIAA could be indicative of lower 5-HT 
synthesis (reflecting the tendency for the lower availability of tryptophan, the 
precursor for 5-HT) in PS-1 Tg mouse samples.  Even though the cerebellum had 
only an increased MAO-A activity, as opposed to the cortex which had increases in 
both MAO-A and MAO-B, there seems to be more of an effect occurring in PS-1 Tg 
mice within this area.  This occurrence could be attributed to the fact that basal 
MAO-A activity is increased approximately 25% in the cerebellum compared to WT, 
while in the cortex basal activity was only increased by approximately 12% 
compared to WT.  Combining this with the fact that both brain regions have Ca2+-
sensitive increases in MAO-A activity and that MAO-A is more predominant in 
noradrenergic neurons (59), then it would not be unreasonable to assume that MAO-
A substrates could presumably be affected more in the cerebellum of PS-1 Tg mice.  
Although MAO activity was not determined in hippocampal extracts because of the 
limited quantity of tissue, analysis of biogenic amine levels revealed equal or larger 
amounts of DOPAC and HVA, perhaps reflecting the significantly higher levels of 
DA in this tissue. 
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Figure 4.1: Biogenic amine metabolism.  MAO catalyzed biogenic amine 
metabolism is noted in red. (Enzymes abbreviations are AD (aldehyde 
dehydrogenase), ADH (alcohol dehydrogenase), COMT (catechol-o-methyl 
transferase), DβH (dopamine β-hydroxylase), MAO (monamine oxidase), PNMT 
(phenylethanolamine-N-methyltransferase); amine abbreviations are 3-MT (3-
methoxytyramine), 5-HIAA (5-hydroxyindole acetic acid), 5-HT (serotonin), A 
(adrenaline), DA (dopamine), DOPAC (3, 4-dihydroxyphenylacetic acid), HVA 
(homovanillic acid), MHPG (3-Methoxy-4-hydroxyphenylethyleneglycol), ME 
(Metanephrine), NA (noradrenaline), and VMA (vanillylmandelic acid). 
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 Even though the exact relationship between specific familial AD PS-1 
mutations and Ca2+ remains unclear, it is apparent that the individual PS-1 proteins 
do affect MAO-A (and MAO-B) basal and Ca2+-sensitive activities, both in cell 
cultures and ex vivo, thus indicating that the effects of PS-1 proteins on MAO are not 
simply restricted to their ability to affect Ca2+ levels. 
 
 
4.2 Direct PS-1 effects 
 
 The differences in MAO activity between WT and PS-1 Tg mice and 
between different brain regions could be indicating differences in protein levels.  
This, however, did not appear to be the case as cortical and cerebellar protein 
extracts from PS-1 Tg mice have similar, or even slightly less, respectively, MAO-A 
protein levels than did WT mouse extracts.  MAO-B protein levels were the same in 
PS-1 Tg and WT mice.  Therefore, the increased MAO activity in PS-1 Tg mice 
cannot be attributed to corresponding increases in MAO protein levels.  Interestingly, 
examination of protein levels in hippocampal extracts revealed a slight decrease in 
full-length MAO-A proteins levels and an increase in MAO-A protein fragments 
migrating at approximately 49 kDa.  Even more surprising was that in all three brain 
regions full length MAO-A was almost completely lost in bigenic APP/PS-1 mice (a 
commonly used model for AD-related pathology).  Therefore it is possible that 
mutated PS-1 proteins are able to cleave full-length MAO-A proteins through 
proteolytic processing. 
As the regionally-specific effects in PS-1 Tg mice brains was only observed 
with the Ca2+-sensitive component of MAO activity, the expression levels of two 
proteins known to affect either PS-1 function and/or MAO function were examined.  
These were calbindin (which was shown by Guo et al (124) to suppress any PS-1-
mediated toxicity and by Cao et al (111) to inhibit MAO-A activity) and activated 
p38 MAPK (which was recently found in our laboratory to phosphorylate MAO-A 
and to inhibit Ca2+-sensitive MAO-A activity).  Although the expression levels of 
both proteins were not detectably different between WT and PS-1 brain extracts, 
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their influence on MAO-A activity in vivo can not be conclusively excluded; for 
example, their influence might have occurred at a much earlier time (note, the 
animals tested were already six months of age) or their subcellular distribution, and 
hence their influence, might have changed, although this would not be readily 
detectable by western blot analysis.  
The observation that MAO-A protein could be cleaved in PS-1 Tg mouse 
brain was very exciting as this would be the first time that this would have been 
observed. To determine if this could be reproduced in cell cultures, a peripheral cell 
line, HEK 293A, and two neuronal cell lines, HT-22 and PC12, were used.  Co-
expression of MAO-A with our original five PS-1 constructs revealed that the 
overexpression of the PS-1 Y115H mutant resulted in an almost complete loss of full 
length MAO-A in HT-22 and HEK 293A cells; MAO-A was only modestly 
diminished in PC12 cells.  This loss of full-length MAO-A was not accompanied by 
a loss of MAO-A activity, suggesting that it is not the full length MAO-A species 
that is the active species (or not exclusively).  In HEK 293A cells this loss was 
accompanied by the conspicuous appearance of an N-terminal fragment.  It is 
interesting to note that the catalytically inactive PS-1 D257A protein could also 
reduce full-length MAO-A (although to a lesser extent than the PS-1 Y115H mutant) 
in HT-22 and HEK 293A cells (which was reflected in a loss in MAO-A activity). 
 The reduced MAO-A full-length protein found in various PS-1 M146V Tg 
mouse brain regions and in three different cell lines suggest that MAO-A might be a 
putative substrate of PS-1.  If this is true, then the two proteins must associate in 
order for this cleavage to occur.  Immunoprecipitation of overexpressed PS-1 
proteins revealed that the three familial AD-related mutants (Y115H, ΔEx9 and 
M146V) and PS-1 WT all directly interacted with MAO-A; the PS-1 Y115H protein 
was the only one to also associate strongly with MAO-B.  As the PS-1 D257A 
protein associated very weekly with either of the MAO isoforms, it suggests that it 
either binds very weakly with MAO proteins or that the PS-1 and MAO association 
is not direct, but rather in a larger complex.  This possibility is reasonable as 
previous work from our laboratory indicates that the MAO-A protein exists in a 
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large molecular weight complex (> 200 kDa), which could include several proteins 
including PS-1/γ-secretase. 
 If PS-1 is proteolytically processing the MAO-A protein, then MAO-A must 
bind to the PS-1 substrate binding site.  Both tissue extracts and cell culture extracts 
were incubated with DAPT, a chemical that is believed to allosterically or directly 
modulate γ-secretase activity by preventing the passage of substrate from PS-1’s 
binding site to its catalytic site (131).  DAPT treatment consistently increased MAO-
A activity in PS-1 M146V-transfected cells and in PS-1 M146V Tg mice cortical 
homogenates, in a DAPT concentration-dependent manner.  As this occurred in vitro 
(with a maximum incubation time of 10 min), the increase in MAO-A activity can 
not be the result of either de novo protein synthesis or post-translational processing.  
A more acceptable explanation is that DAPT is acting as a competitive antagonist.  
In other words, DAPT is competing with MAO-A for access to the PS-1 binding site 
and releasing MAO-A from the PS-1/MAO-A complex.  The subsequent increase in 
MAO-A activity suggests that the association between PS-1 and MAO-A inhibits 
MAO-A activity.  If this is true, then this would represent a novel endogenous means 
of regulating MAO-A activity. 
 The potential clinical relevance of this work needs to be addressed. While the 
implications to AD and related neurodegenerative diseases are obvious, this work 
also provides a basis for the depression that is often associated with AD. MAO-A is 
known to play a role in several mental disorders (132) and relatively modest changes 
in MAO-A activity/function can have important neuropsychiatric consequences as 
demonstrated by the fact a 34% increase in [11C]-harmine-labeled MAO-A is 
observed in brains of untreated depressed patients compared to controls, yet MAO-A 
appears to be the major contributor to neurotransmitter metabolism in these same 
patients (133). Furthermore, and perhaps most relevant to the present work, 
depression might promote cognitive impairment and be a risk factor for AD (134). 
Perhaps subtle changes in PS-1 function that might not be sufficient to promote 
aberrant APP processing to the toxic Aβ peptide and any AD-related pathology, 
could affect MAO function (and its sensitivity to Ca2+). This, in turn, could 
predispose to depression not only in the sub-clinical AD population, but perhaps 
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more importantly, could also predispose to depression in the general psychiatric 
population itself. Thus, a simple genetic screening for PS-1 mutations might be 
useful for AD-related neurodegeneration as well as for other MAO-related 
psychiatric disorders, including depression. 
 Taken together, this thesis work provides the groundwork for a relationship 
between PS-1 and MAO-A function.  Specifically, PS-1 (i) can indirectly affect 
MAO-A through its sensitivity to Ca2+, and (ii) can directly affect MAO-A by a 
possible PS-1/γ-secretase-mediated proteolytic event.  The latter not only suggests 
that MAO-A is a novel substrate for PS-1/γ-secretase, but that the association 
between PS-1 and MAO-A seems to inhibit MAO-A activity.  If PS-1 is mutated, 
such as in familial AD, then it increases its tendency to cleave MAO-A into smaller 
(active?) fragments. 
 
In summary, from all our experiments, we conclude that: 
1) PS-1 is able to alter intracellular Ca2+ levels and PS-1 Y115H and PS-1 D257A 
may also be involved in altering Ca2+ distribution.  
2) In cells, the PS-1 mutations, particularly the Y115H and ΔEx9 variants, increase 
basal and Ca2+-sensitive MAO-A activities. The Ps-1 M146V mutation 
specifically affects Ca2+-sensitive MAO activity.  Only the effects of PS-1 
Y115H are calbindin-sensitive. 
3) In transgenic mice, expressing the PS-1 M146V mutant protein, there is an 
increase in basal and Ca2+-sensitive MAO-A (cerebellum>cortex).  Cortical 
MAO-B activity appears to respond to Ca2+ in these same mice.  
4) Full-length MAO-A is lost in cells co-expressing PS-1 Y115H and MAO-A.  
MAO-A fragments are evident in the hippocampus of PS-1 mice and in HEK 
293A cells co-expressing PS-1 Y115H and MAO-A. 
5) The PS-1 Y115H protein is the only protein that can directly interact with both 
MAO isoforms. 
6) Inhibition of PS-1 M146V by DAPT causes an increase in MAO-A activity, 
 suggesting a competitive inhibition of the PS-1 binding site could release 
 MAO-A and allow for its activation. 
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4.3 Future directions 
  
 Because many of the findings from this work have never been presented 
before there are still many in vitro and in vivo experiments that are necessary.  First 
it would be important to quantitate the effects of the PS-1 constructs on Ca2+ levels 
or distribution within the cell.  Second, it is necessary to know to what extent, if any, 
MAO-A cleavage is similar to other familiar PS-1 substrates such as APP and Notch.  
Based on this, MAO-A truncation mutants could be generated to see if truncated 
MAO-A protein retains activity.  Lastly, it would be critical to determine how much 
of the increased MAO-A activity (by full-length or smaller MAO-A peptides) 
contributes to hydroxyl radical production and oxidative stress in the brain.  Well-
known reagents such as the hydrogen peroxide-binding DCFDA can be used for this 
purpose.  These experiments should elucidate the mechanism(s) by which PS-1 (and 
Ca2+) affects MAO activity and to what degree this increased MAO activity (and 
sensitivity to Ca2+) is implicated in the neurodegeneration occurring in AD. 
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